ALUMINIUM HYDROXIDE,"Oral suspension: Aluminium hydroxide 250 mg/5 ml and Magnesium hydroxide 250 mg/5 ml; Tablets/Gel: may contain simethicone, and some contain algenic acid",Ulcer and non ulcer dyspepsia; gastro-oesophageal reflux.,"Hypophosphatemia, undiagnosed GI or rectal bleeding, appendicitis, porphyria, renal impairment (aluminium may accumulate), constipation, hepatic impairment, dehydration.",Tablets: 1-2 tablets chewed 4 times a day and at bed time or as required; Suspension: 5-10 ml 4 times daily between meals and at bedtime; Children (6-12 years): up to 5 ml 3 times daily,"Constipation, haemorrhoids, fissures, faecal impaction","Decreases absorption of digoxin, azithromycin, ciprofloxacin, norfloxacin, rifampicin, tetracycline, isoniazid Patient information: Take with water to decrease constipation"
MAGNESIUM HYDROXIDE,"Oral suspension: Aluminium hydroxide 250 mg/5 ml and Magnesium hydroxide 250 mg/5 ml; Tablets/Gel: may contain simethicone, and some contain algenic acid","Ulcer and non ulcer dyspepsia, gastro-oesophageal reflux","Severe renal impairment, renal impairment, hepatic impairment.","250-500 mg, per oral 3-4 times a day","Diarrhoea in renal impairment, respiratory depression, hypotension, loss of tendon reflexes, cardiac arrest",Decrease absorption of other drugs Patient information: Do not take this medicine within 2 hours of taking other medicines (especially flouroquinolones); causes diarrhoea
ATROPINE SULPHATE,Injection: 0.6 mg/ml,"Gastrointestinal spasm, renal colic, anesthetic premedication, OP poisoning","Avoid in case of angle closure glaucoma, hypersensitivity, tachycardia secondary to cardiac insufficiency or thyrotoxicosis. Use in pregnancy only when potential benefits justify possible risk to fetus.",,"Premedication: intravenous injection, 200-600 micrograms immediately before induction of anesthesia and in incremental doses of 100 micrograms for the treatment of bradycardia; intramuscular injection, 300-600 micrograms 30-60 minutes before induction; child 20 micrograms/kg; For control of muscarinic side effects of neostigmine: in reversal of competitive neuromuscular block, by intravenous injection, 0.6-1.2 mg; Bradycardia: particularly complicated by hypotension after myocardial infarction, intravenous injection of 300 micrograms, increasing to 1 mg if necessary; Antidote to organophosphorous poisoning: by intramuscular or intravenous injection, 1 to 2 mg, repeated in 20-30 minutes as soon as cyanosis has cleared","Anticholinergic effect is more pronounced with tricyclic antidepressants, amantidine, antiparkinsonism agents; decreases the absorption of ketoconazole, levodopa; antacids decrease the effect of atropine Patient information: Do not perform strenuous activity in high temperatures, heat stroke may occur; do not perform tasks requiring motor co-ordination and alertness (e.g. driving)"
DROTAVERINE,"Tablet: 10 mg, 40 mg and 80 mg; Injection: 20 mg/ml","Gastrointestinal colicky pain, renal colic, 1st stage of labour (dilation of cervical opening)","Paralytic ileus (or about to undergo surgery), gall bladder disease, diabetes, depression, ulcerative colitis, heart disease, liver disease, kidney disease",40-80 mg 3 times per day,"Nausea, vomiting, fainting, dry mouth",
FLAVOXATE HYDROCHLORIDE,Tablet: 100 mg and 200 mg,"Increased urinary frequency and incontinence, bladder spasms due to catheterization, urgency, dysuria","Obstructive uropathy, ileus, GI obstruction, GI bleeding, glaucoma",200 mg 3 times daily,"Same as in hyoscine, fatigue, vertigo",Can be taken without regard to food Patient information: Do not perform tasks requiring motor co-ordination/alertness (e.g. driving)
HYOSCINE BUTYL BROMIDE,Tablet: 10 mg and 20 mg; Injection: 20 mg/ml,"Symptomatic GI and pain to urinary spasm, irritable bowel syndrome, excessive respiratory secretion, bowel colic","Pregnancy, geriatric patient, hyperthyroidism, dysarrhythmias, ulcerative colitis, hypertension, renal disease, hepatic disease, urinary retention",10 mg 3 times a day; 4 to 20 mg 4 times a day,"Headache, confusion, dizziness, hallucination, palpitation, tachycardia, blurred vision, tachycardia, blurred vision, photophobia, cycloplegia, dry mouth, constipation, paralytic ileus",
MEBEVERINE HYDROCHLORIDE,Tablet: 135 mg; Suspension: 50 mg/5ml,"Irritable bowel syndrome, other spasmodic conditions",Paralytic ileus. To be taken 20 minutes before meal,135-150 mg 3 times a day to be taken 20 minutes before meal,"Allergic reaction, angioedema, urticaria, rash",
CIMETIDINE,Tablets: 200 mg and 400 mg; Injection: 100 mg/ml,"Benign duodenal and gastric ulcer, reflux oesophagitis, Zollinger–Ellison syndrome, GERD, stress ulcer","Hypersensitivity, pregnancy, impaired renal function, children<12 years. Sexual dysfunction in male (loss of libido, impotence, gynaecomastia)","Benign ulcer (oral): 400 mg twice daily followed by 800 mg once at night for 4 weeks, maintainence 400 mg at night; Child: 25-30 mg/kg; Infant: 20 mg/kg in divided doses; Injection(IM): 200 mg every 4-6 hrs, Injection(IM): 200 mg slowly over 2 minutes; IV infusion: 400 mg in 100 ml of normal saline over ½-1 hours, 50-100 mg/hour over 24 hrs for continuous infection","Headache, dizziness, myalgia, nausea, skin rash and diarrhoea or constipation, gynaecomastia, microsomal enzyme inhibition and hepatotoxicity are higher","Decreases absorption of sucralfate, decreased absorption by ketoconazole, itraconazole"
ESOMEPRAZOLE,Tablets: 20 mg and 40 mg; Injection: 40 ml/vial,"Benign gastric and duodenal ulcer, NSAID associated duodenal or gastric ulcer, duodenal or benign gastric ulcer associated with Helicobacter pylori, reflux oesophagitis, Zollinger–Ellison syndrome, stress ulcer","Hypersensitivity reaction, breast-feeding, patients with liver disease","Duodenal ulcer associated with H. pylori: 20 mg twice daily; NSAID associated GU: 20mg once daily for 4-8 weeks; for prophylaxis with increase rate of gastroduodenal complication who require continued NSAID treatment 20 mg daily GERD: 40 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptom persist, maintenance 20 mg daily","Nausea, vomiting, diarrhoea, abdominal colic, skin rash, headache and dizziness","Inhibits hepatic metabolism of diazepam, phenytoin, flurazepam, digoxin etc; increases the bleeding tendency with warfarin Patient information: Avoid alcohol, salicylates, NSAIDs; avoid excessive amounts of caffeine; report onset of black tarry stools, diarrhoea, abdominal pain"
FAMOTIDINE,Tablets: 20 mg and 40mg; Injection: 10 mg/ml,"Benign duodenal and gastric ulcer, reflux oesophagitis, Zollinger–Ellison syndrome, GERD, stress ulcer","Hypersensitivity, pregnancy, impaired renal function, children<12 years. Sexual dysfunction in male (loss of libido, impotence, gynaecomastia)","Benign ulcer: Oral 40 mg at night for 4-8 weeks, maintenance dose 20 mg at night; Reflux oesophagitis: 20-40 mg twice daily for 5-12 weeks; Zollinger–Ellison syndrome: 20 mg every 6 hours","Headache, dizziness, myalgia, nausea, skin rash and diarrhoea or constipation","Decreases absorption of sucralfate, decreased absorption by ketoconazole, itraconazole Patient information: Avoid alcohol, NSAIDs, extreme hot and spicy foods"
LANSOPRAZOLE,Capsule: 15 mg and 30 mg,"Benign gastric and duodenal ulcer, NSAID associated duodenal or gastric ulcer, duodenal or benign gastric ulcer associated with Helicobacter pylori, reflux oesophagitis, Zollinger–Ellison syndrome, stress ulcer","Hypersensitivity reaction, breast-feeding, patients with liver disease","Duodenal ulcer: 30 mg daily in morning for 4 week, maintenance 15 mg daily; Benign gastric ulcer: 30 mg daily in morning for 8 week; NSAID associated duodenal or gastric ulcer: 15-30 mg once daily for 4 weeks continued for further 4 weeks if not fully healed; Reflux oesophagitis: 30 mg daily in morning for 4 weeks, continued for further 4 weeks if not fully healed; Zollinger-Ellison syndrome: initially 60 mg once daily adjusted according to response, daily dose of 120 mg or more given in two divided doses; Reflux oesophagitis refractory to other treatment: 40 mg for 8 weeks","Nausea, vomiting, diarrhoea, abdominal colic, skin rash, headache and dizziness","Inhibits hepatic metabolism of diazepam, phenytoin, flurazepam, digoxin etc; increases the bleeding tendency with warfarin Patient information: Avoid alcohol, salicylates, NSAIDs; avoid excessive amounts of caffeine; report onset of black tarry stools, diarrhoea, abdominal pain"
OMEPRAZOLE,Capsule: 10 and 20mg,"Benign gastric and duodenal ulcer, NSAID associated duodenal or gastric ulcer, duodenal or benign gastric ulcer associated with Helicobacter pylori, reflux oesophagitis, Zollinger–Ellison syndrome, stress ulcer","Hypersensitivity reaction, breast-feeding, patients with liver disease",Adult: 20 mg/day for 4-8 week,"Nausea, vomiting, diarrhoea, abdominal colic, skin rash, headache and dizziness","Inhibits hepatic metabolism of diazepam, phenytoin, flurazepam, digoxin etc; increases the bleeding tendency with warfarin Patient information: Avoid alcohol, salicylates, NSAIDs; avoid excessive amounts of caffeine; report onset of black tarry stools, diarrhoea, abdominal pain"
PANTOPRAZOLE,Tablets: 20 and 40mg; Injection: 40 mg/vial,"Benign gastric and duodenal ulcer, NSAID associated duodenal or gastric ulcer, duodenal or benign gastric ulcer associated with Helicobacter pylori, reflux oesophagitis, Zollinger–Ellison syndrome, stress ulcer","Report severe diarrhoea, black tarry stools, abdominal pain, product may have to be discontinued. Hypersensitivity reaction, breast-feeding, patients with liver disease",Duodenal ulcer: 40 mg daily in the morning for 2 weeks; Benign gastric ulcer: 40mg daily in the morning for 2 weeks,"Nausea, vomiting, diarrhoea, abdominal colic, skin rash, headache and dizziness","Inhibits hepatic metabolism of diazepam, phenytoin, flurazepam, digoxin etc; increases the bleeding tendency with warfarin Patient information: Avoid alcohol, salicylates, NSAIDs; avoid excessive amounts of caffeine; report onset of black tarry stools, diarrhoea, abdominal pain"
RABEPRAZOLE,Tablet: 10 mg and 20 mg,"Benign gastric and duodenal ulcer, NSAID associated duodenal or gastric ulcer, duodenal or benign gastric ulcer associated with Helicobacter pylori, reflux oesophagitis, Zollinger–Ellison syndrome, stress ulcer","Hypersensitivity reaction, breast-feeding, patients with liver disease, children - not recommended","Benign gastric ulcer: 20 mg daily in the morning for 6 weeks, continued for further 6 weeks if not fully healed; Duodenal ulcer: 20 mg daily in the morning for 4 week continued for further 4 week if not fully healed; GERD: 20 mg once daily for 4-8 weeks, maintenance 10-20mg daily","Nausea, vomiting, diarrhoea, abdominal colic, skin rash, headache and dizziness","Inhibits hepatic metabolism of diazepam, phenytoin, flurazepam, digoxin etc; increases the bleeding tendency with warfarin Patient information: Avoid alcohol, salicylates, NSAIDs; avoid excessive amounts of caffeine; report onset of black tarry stools, diarrhoea, abdominal pain"
RANITIDINE,Tablets: 150 mg and 300 mg; Injection: 25 mg/ml,"Benign duodenal and gastric ulcer, reflux oesophagitis, Zollinger–Ellison syndrome, GERD, stress ulcer","Hypersensitivity, pregnancy, impaired renal function, children<12 years. Sexual dysfunction in male (loss of libido, impotence, gynaecomastia)","Benign ulcer: oral 150 mg twice daily, 300 mg at night for 4-8 weeks; Chronic episodic dyspepsia: 6 weeks; NSAID induced ulcer: for 8 weeks; Reflex oesophagitis: 150 mg twice daily, 300 mg at night for 8 weeks, or if necessary 12 weeks; Gastric acid reduction (Prophylaxis of acid aspiration in obstetric): oral – 150 mg at onset of labour, then every 6 hours; Surgical procedure: IM or slow IV injection, 50 mg 45-60 minutes before induction of anaesthesia, oral 150 mg 2 hours before induction of anaesthesia, IM 50 mg every 6-8 hours IV infusion, 25 mg/hour for 2 hours, repeated every 6-8 hours.","Headache, dizziness, myalgia, nausea, skin rash and diarrhoea or constipation","Decreases absorption of sucralfate, decreased absorption by ketoconazole, itraconazole"
SUCRALFATE,Tablet: 1 g,"Benign gastric and duodenal ulceration, chronic gastritis","Pregnancy, safety and efficacy of sucralfate in children have not been established","2 g twice daily (on rising and at bed time) for 4-6 week or in resistant case 12 weeks, morning 8 g daily; Prophylaxis of NSAIDs induced ulcer (suspension) 1 g 6 times daily (maximum 8 g daily)",,"Concomitant use with cimetidine, phenytoin, tetracyclines and fluoroquinolones result in reduction in bioavailability of these drugs. It should be taken at least 2 hours after administration of other drugs Patient information: Complete full course of treatment to ensure ulcer healing, increase fluid intake, dietary bulk and exercise to prevent constipation"
CYCLIZINE,Tablets: 25 mg and 50 mg,"Prevention and treatment of nausea, vomiting and vertigo associated with motion sickness","Asthma, glaucoma, emphysema, chronic pulmonary disease. Should not be concurrently used with sedatives, tranquilizers and anticholinergic medication","Motion sickness: 50 mg 30 minutes before traveling, can be repeated in 6 hours (up to 200 mg/day), 6-12 hours, 25 mg up to 3 times/day not to exceed 75 mg/day","Drowsiness, xerostomia, headache, dermatitis, urinary retention, diplopia Patient information: Avoid hazardous activities, activities requiring alertness because dizziness may occur; avoid alcohol, other CNS depressants; take 30 minutes before travelling",
DIMENHYDRINATE,Tablet: 50 mg; Injectable: 50 mg/ml,"Prevention of motion sickness, Meniere’s disease","Hypersensitivity, pregnancy and neonates, breast-feeding, seizures, angle closure glaucoma, benign enlargement of prostate. Masks early signs of ototoxicity if given consistently with ototoxic drugs","Prevention of motion sickness: 50-100 mg 4-6 hours or 30 minutes before traveling (not to exceed 400mg/day); Meniere’s disease: 50 mg intra-muscular for acute attack, 25-50 mg 8 hourly for maintenance","Paradoxical CNS stimulation (children & occasionally in adults), CNS depression, dizziness","Eluxadoline, sodium oxalate increases effects by pharmacodynamics synergism Patient information: Avoid hazardous activities, activities requiring alertness because dizziness may occur; avoid alcohol, other CNS depressants"
DOMPERIDONE,Tablet: 10 mg; Suspension: 1 mg/ml,"Antiemetic, gastrokinetic to accelerate gastric emptying, dyspepsia, GERD (Gastro esophageal reflux disease)","Obstruction to GIT, urinary outflow, paralytic ileus, comatose condition, hepatic and cardiovascular disease, glaucoma",Acute nausea and vomiting: 10-20 mg 6-8 hours (child 0.25-0.5 mg/kg); Functional dyspepsia: 10-20 mg 3 times daily before food for maximum of 12 hours,"Galactorrhoea, gynaecomastia, decreased libido, skin rashes",Anticholinergic drugs may reduce the therapeutic effects of domperidone Patient information: Avoid grapefruit juice during therapy
METOCLOPRAMIDE,Tablet: 10 mg; Injection: 5 mg/ml,"Nausea and vomiting in GI disorders and treatment with cytotoxic or radiotherapy, GERD, gastroparesis, premedication and post operatively","Gastro intestinal obstruction, haemorrhage or perforation, 3-4 days after GI surgery, pheochromocytoma, convulsive disorders, renal and hepatic impairment, elderly, children, pregnancy and breast feeding, Parkinson’s disease, epilepsy, depression, porphyria. Assess for extra-pyradimal side effects (difficulty in speaking, loss of balance, rigidity, tremor), signs of depression","Nausea and vomiting, GERD, Gastroparesis: Adult: 10 mg 3 times daily (children 2-5 mg/kg); Premedication: 10 mg single dose; Aid to gastrointestinal procedure: 10-20 mg as single dose 5-10 minutes before examination","Extrapyramidal symptoms (children and young adult), tardive dyskinesia on prolonged use, hyperprolactinemia, drowsiness, dizziness, restlessness, headache, neuroleptic malignant syndrome, rashes, pruritus, cardiac conduction abnormalities following IV administration","Alcohol, other CNS depressants increase sedation effects. haloperidol, phenothiazines increase risk for EPS Patient information: Avoid concurrent use of alcohol and other CNS depressants"
ONDANSETRON,"Injectable: 2 mg/ml; Tablet: 4 mg, 8 mg and 24 mg; Oral solution: 4 mg/5ml","Chemotherapy induced nausea and vomiting, post operative nausea and vomiting, radiation induced nausea and vomiting, uremic pruritus, rosacea, hyperemesis gravidarum","Hypersensitivity reactions, co-administration with apomorphine, pregnancy, breastfeeding, moderate to severe liver impairment; child below 4 years of age - safety and efficacy not established","Chemotherapy induced nausea and vomiting: moderate - 8 mg started 30 minutes prior, highly emetogenic 24 mg; IV - 0.15 mg/kg over 15 minutes, 30 minutes prior to chemotherapy then 4 and 8 hours; Postoperative nausea and vomiting : 4 mg IV/IM before anaesthesia as after procedures; Radiation induced nausea and vomiting: 8 mg PO 1-2 hours before radiation, subsequent doses every 8 hours; Cholestatic pruritus: 8 mg 12 hours or 8 hours for 7 days; Uremic pruritus: 8 mg 12 hours or 8 hours for 14 days, Child below 4 years of age: Safety and efficacy not established, can be given 0.1 mg/kg IV in postoperative nausea &vomiting","Headache, constipation, hiccups, flushing, transient visual disturbances, involuntary movements, dizziness, arrhythmia, hypotension Patient information: Report to health care professional immediately if symptoms of irregular heart beat or involuntary movement of eyes, face or limbs occur",
PROCHLORPERAZINE,Injection: 12.5 mg/ml; Tablets: 5 mg and 25 mg,"Postoperative nausea and vomiting, chemotherapy induced nausea and vomiting, vertigo, psychosis","Coma, hypersensitivity. Should be protected from light",Acute attack of vomiting: 20 mg initially then 10 mg after 2 hours; Prevention of nausea and vomiting: 5-10 mg 2-3 times daily (0.25 mg/kg); Labyrinthine disorders: 5 mg 3 times daily (up to 30 mg daily in divided doses),"Muscle dystonia and other extrapyramidal side effect, dry mouth, drowsiness","Increase serotonin syndrome, neuroleptic malignant syndrome with SSRIs, SNRIs Patient information: Avoid hazardous activities, activities requiring alertness, alcohol; not to double or skip doses; avoid sun, wear sunscreen, protective clothing"
PROMETHAZINE,"Tablets: 25 mg, 50 mg and 125 mg; Syrup: 6.25 mg/ml; Suppository: 25 mg, 50 mg and 125 mg; Injection: 25 and 50 mg/ml","Nausea, vomiting, motion sickness, pre-operative and post-operative sedation, obstetric sedation","Porphyria, child under 2 years (risk of respiratory depression), pregnancy. May cause photosensitivity","Nausea and vomiting: PO/PR 12.5-25 mg 4-6 hours, IV/IM 12.5-25 mg 4-6 hours; Motion sickness: 25 mg PO/PR 30-60 minutes before travel; Pre-operative sedation: 50 mg PO/PR on night before procedure; Post-operative: 25-50 mg IV/IM combined with reduced doses of analgesics; Allergic conditions: 25 mg at bedtime or 12.5 mg (PO/PR), 25 mg may be repeated in 2 hours (IV/IM)","Sedation, blurred vision, confusion, hallucination, disorientation, extrapyramidal symptoms","May potentiate the sedative action of opiates, other CNS depressants, antihistamines and alcohol Patient information: Avoid prolonged exposure to sunlight, avoid concurrent use of alcohol or other CNS depressants"
DIPHENOXYLATE,Tablet: 2.5 mg diphenoxylate and 0.025 mg atropine,"Acute diarrhoea, chronic mild ulcerative colitis","Children <4 years, hypersensitivity, hepatorenal disease, pregnancy, obstructive jaundice, abnormal liver function, diarrhoea, pseudomembranous colitis, pregnancy, breast feeding, hepatic disease, ulcerative colitis, hypertensive crisis","Initial dose for adults is 4 tablets, followed by 2 tablets every 6 hours until diarrhoea is controlled. Maintenance dose as low as ¼th of initial dose","Blurred vision, sedation, nausea, vomiting, abdominal discomfort, dryness of mouth, urinary retention","Antimuscarinics, opioids and analgesics, avoid in those with NAD inhibitors"
LOPERAMIDE,Tablet: 2 mg,"Acute nonspecific diarrhoea, chronic diarrhoea, faecal incontinence, pain of intestinal colic","Active ulcerative colitis, antibiotic associated colitis, condition where abdominal distention develops, condition where inhibition of peristalsis should be avoided. Hypersensitivity, bloody diarrhoea, high fever, infectious diarrhoea; pseudomembranous colitis, age<2 years. Patients in whom constipation must be avoided. Avoid use as primary therapy with acute dysentery. Discontinue if no improvement seen within 48 hours in patient with acute diarrhoea, symptoms worsen or abdominal swelling or bulging develops","Acute diarrhoea: Initially 4 mg, followed by 2 mg for up to 5 days; usual dose 6 to 8 mg daily; maximum 16 mg per day; Chronic diarrhoea: Initially 4 to 8 mg daily in divided doses; subsequently adjusted accordance to response, maintenance up to 16 mg daily in 2 divided doses","Dizziness, drowsiness, fatigue, flatulence, headache, nausea","Eluxadoline and fentanyl increase chance and severity of constipation Patient information: Do not take missed doses, do not double dose"
ORAL REHYDRATION SALTS,"Sachet: 2.6 g/l sodium chloride, 2.9 g/l sodium citrate (dihydrate), 1.5 g/l potassium chloride,13.5 g/l glucose (anhydrous)",Dehydration from acute diarrhoea,Renal impairment. Should be protected from moisture,Fluid and electrolyte loss in acute diarrhoea: oral - adult 200-400 ml solution after every loose motion; infant 1-1.5 times usual feed volume; child 200 ml after every loose motion,"Vomiting (too rapid administration), hypernatremia and hyperkalaemia (overdose in renal impairment or administration of too concentrated solution) Patient information: One sachet should be used to prepare one litre of solution, discard any unused solution after 24 hours; do not boil/dilute the solution",
RIFAXIMIN,Tablet: 200 mg and 550 mg,"Traveller’s diarrhoea, hepatic encephalopathy, irritable bowel syndrome","Hypersensitivity, pregnancy category C, breast feeding. Not effective in traveller’s diarrhoea due to organism other than E. coli; discontinue if symptoms worsen or persist > 24-48 hours; hepatic impairment. Possibility of pseudomembranous colitis","Traveller’s diarrhoea: oral, 200mg TDS for 3 days; Hepatic encephalopathy (maintenance of remission): oral, 550mg BD; Irritable bowel syndrome: oral, 550 mg TDS for 14 days","Flatulence, rectal tenesmus, abdominal pain, defecation urgency, constipation, nausea, vomitting",
ZINC SULFATE,"Oral solution: 10 mg/5 ml; Tablet: 10 mg, 20 mg",Adjunct to ORS in acute diarrhoea,Acute renal failure (may accumulate),Infants<6 months: 10 mg daily for 10-14 days; Child 6 months-5 years ronic diarrhoea: 20 mg daily for 10-14 days,"Abdominal pain, dyspepsia, Nausea, Vomiting, Diarrhoea, Headache, Gastric irritation","Absorption of ciprofloxacin, levofloxacin, ofloxacin, ferrous salt and calcium salt can be reduced Patient information: Tablets may be dispersed in breast milk, in oral rehydration solution or in water on a small spoon, older children may chew tablets or swallow them with water; inform doctor if severe nausea/vomiting, abdominal pain or tarry stools seen"
ISPAGHULA HUSK,"Powder (in plastic bottles): 50 g, 100 g, 200 g, 500 g",Constipation,Useful to patient who cannot tolerate bran,"0.5-2 gm/day (3 tea spoonful) at bed time, children ½ of adult dose","Abdominal distension, flatulence Patient information: increase fluid intake, bulk forming foods in diet and mobility",
DOCUSATE SODIUM,Tablet: 100 mg; Syrup: 50 mg/ml; Drops: 25mg/drop,"Constipation, adjunct to radiological procedure (with Barium meal 400 mg)","Hypersensitivity reaction, intestinal obstruction, prolong use and children","50-300 mg per oral single or divided dose (up to 500 mg), initially large dose, gradually decrease dose, with barium meal 400 mg","Rashes, transient abdominal cramping pain",
LIQUID PARAFFIN,Emulsion: 25% v/v,Constipation,Hypersensitivity reactions,10-30 ml at night,"Lipoid pneumonia due to aspiration, interfere fat soluble vitamin absorption, Foreign body granulomatous lesion on mesenteric, liver and spleen",
BISACODYL,"Tablet: 5 mg, 10 mg; Suppository: 5 mg, 10 mg","Constipations, bowel preparation for radiology and surgery","Intestinal obstruction, pregnancy, children<4 years.","Constipation: 5-10 mg (oral) at night, 10 mg at morning suppository; Radiological procedure: 10 mg per oral at night then 10 mg suppository at morning, 1 hour before procedure; Paediatric: >6 yr, 5 mg per oral at night, <10 yrs, 5 mg suppository; Radiological procedure: 5 mg by mouth at night, 5 mg per rectal at morning","Abdominal cramp, local irritation","Increase risk of mucusoal ulceration while coadminstering with sodium sulfate, potassium sulfate or magnesium sulfate. May produce hypokalemia with deflazacort or dichlorphenamide. Patient information: Better to be taken in empty stomach, to be taken with full glass of water. Swallow tabs whole with full glass of water; do not break, crush, chew tabs. alone only with water for better absorption. Do not take with antacid with in 1 hour"
SENNA,Tablet: 7.5 mg,"Constipation, bowel preparation for radiological and surgical procedure","Avoid in children and pregnancy, intestinal obstruction. Should be avoided except when straining, increased risk of rectal bleeding in haemorrhoids","Constipation: Adult:2-4 tablets at night, Children (>6 years): ½ of adult dose; Bowel preparation: 1 mg/kg in two divided doses",Abdominal cramps,
LACTULOSE,Syrup: 10 mg/15 ml,"Constipation, hepatic encephalopathy","Hypersensitivity, intestinal obstruction, diabetic patient, pregnancy- use if benefit > risk. Take adequate water","Constipation: adult, 15 ml per oral twice daily (not more than 60ml/day) gradually titrate the dose to produce 2-3 soft stool/day; Children: <1 year, 2.5 ml twice a day titrate according to stool frequency, 1-5 years, 5 ml twice a day titrate according to stool frequency, >6-12 years – 10ml twice a day, titrate according to stool frequency; Hepatic encephalopathy: 30-45 ml (20-30 g) per oral to induce rapid detection, 30-45 ml per oral after 6-8 hours","Dehydration, hypernatremia, abdominal distension","Do not use with other laxative (hepatic encephalopathy), increase chance of GI obstruction with nifedipine Patient information: Dilute with fruit juice or water to counteract sweet taste, take in empty stomach for rapid action; may cause belching, flatulence, abdominal cramping"
MACROGOL 3350,"Powder (in satchet): 13.125 g (macrogol 3350) with 0.3507 g sodium chloride, 0.1785 g sodium bicarbonate, 46.6 mg potassium chloride","Constipation, fecal impaction","Gut obstruction, gut perforation, severe inflammatory bowel disease, known hypersensitivity, cardiovascular diseases.","Constipation: dissolve 1 sachet in 125 ml of water, to be taken 1-3 times/day as required; Fecal impaction: dissolve 1 sachet in 125 ml of water, 8 sachets to be taken within 6 hours, up to 3 days if required","Diarrhoea, dehydration, indigestion, pain abdomen, allergic reactions","Anti-epileptics (decreased effectiveness) Patient’s information: Take plenty of fluids. Reconstituted solution can be kept in fridge (2-8oC) and covered, remaining solution to be discarded after 6 hours if not consumed"
MAGNESIUM HYDROXIDE (MILK OF MAGNESIA),"Tablet: 400 mg; Suspension: 7.75%, 400 mg/5ml, 800 mg/5 ml, 1200 mg/5 ml","Constipation, acid peptic disease","Renal failure, acute abdomen, undiagnosed abdominal pain, known hypersensitivity reaction, renal insufficiency","Constipation: 30-60 ml/day per oral at bed time (400 mg/5ml); Acid peptic disease: 5-15 ml (400 mg/5ml) per oral in 4 divided doses, 2-4 tab/day chewable tables","Abdominal cramp, electrolyte imbalance, hypotension Patient information: Shake solution before use. Better to be taken in empty stomach",
MAGNESIUM SULPHATE,"Injectable: 40 mg/ml, 80 mg/ml, 50%; Infusion solution: 1 g/10 ml, 2 g/100 ml","Constipation, hypomagnesemia, eclampsia/severe preeclampsia, preterm labor, torsades de pointes","Renal impairment, abdominal pain, acute surgical abdomenorectal bleeding, heart block",Constipation: 5-10 g dissolved in 24 ml of water,"Flaccid paralysis, circulatory collapse, nausea, vomiting, electrolyte and fluid disturbance","Increases effects of neuromuscular blocker, increases hypotension-antihypertensives, decreases absorption of tetracyclines, fluoroquinolones Patient information: Not to use laxative for long time; shake suspension well before use, not to given at bedtime as laxative may interfere with sleep"
POLYETHYLENE GLYCOL 3350,"Powder (in sachet): 255 g, 527 g",Constipation,"Bowel obstruction, pregnancy category C, children","Constipation: 17 g, after reconstitution in a glass of water","Nausea, abdominal bloating, cramping and flatulence, diarrhoea and excessive stool frequency Patient’s information: Report if unusual cramps, bloating or diarrhoea occurs",
ADALIMUMAB,Injection: 40 mg/0.8 ml prefilled syringe/pen,"Crohn’s disease, ulcerative colitis, rheumatic and psoriatic arthritis, ankylosing spondylitis, plaque psoriasis",,"Crohn’s disease and ulcerative colitis: subcutaneous, initial: 160 mg (given on day 1 or split and given over 2 consecutive days), then 80 mg 2 weeks later (day 15), maintenance: 40 mg every other week beginning day 29",,
BUDESONIDE,Tablet (enteric coated): 3 mg,"Treatment of mild to moderate active Crohn’s disease,","Hypersensitivity, pregnancy cat (C), hepatic impairment","Treatment of mild to moderate active Crohn’s disease: 9 mg orally once daily for up to 8 weeks; Maintenance of clinical remission of mild to moderate Crohn’s disease: 6 mg orally once daily for maintenance of clinical remission up to 3 months (if symptom control maintained, taper doses to complete cessation)","Increased risk of infection, abdominal pain, flatulence, vomitting and other corticosteroid related systemic adverse effects",Avoid using CYP3A4 inhibitors concomitantly
HYDROCORTISONE ACETATE,Suppository: 25 mg,"Ulcerative colitis, proctitis, proctosigmoiditis","Avoid in bowel obstruction preparation, and untreated infection. Proctoscopic examination required before treatment, avoid prolonged use",Suppository 25 mg twice daily for 2 weeks – can be increased up to 25 mg 3 times daily or 50 mg twice daily,"Local pain/burning sensation, rectal bleeding, exacerbation of untreated infections",
INFLIXIMAB,Injection: 100 mg,"Crohn’s disease, ulcerative colitis","Discontinue if serious infection/sepsis, pregnancy (B). Consider premedication with antihistamines, acetaminophen, and/or corticosteroids. Increases risk of lymphoma and other malignancy in children and adolescents","Crohn disease: adult, IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter; dose may be increased to 10 mg/kg in patients who respond but then lose their response. If no response by week 14, consider discontinuing therapy, Children ≥6 years and adolescents, IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter; Ulcerative colitis: IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter, children ≥6 years and adolescents, IV, 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter","Hypersensitivity, abdominal pain, increased serum ALT, infection, infusion related reaction","Adalimumab, etanercept (increases immunosuppressive effect of infliximab)"
MESALAZINE,Tablet: 1.2 g; Suppository: 500 mg; Enema: 5 ml,"Ulcerative colitis (acute attack, maintenance of remission). maintenance of remission of Crohn’s ileo-colitis","Hypersensitivity to salicylates, breast feeding mother, children with chickenpox or flu like symptoms, active peptic ulcer disease, severe renal failure. Empty stomach prior rectal administration of drug; instruct patient on correct method of administration","Maintenance of remission of ulcerative colitis (UC) and Crohn’s ileo-colitis: Adult 1.2-2.4 g daily in divided dosage, child 12-17 years 400-800 mg 3 times/day; Treatment of mild to moderate UC and acute attack: Adult 2.4 g daily in divided dosage, child 12-17 years 800 mg 3 times a day","Dizziness, oligospermia, abdominal pain, flatulence and headache",Preparation that lower stool pH (e.g. lactulose) may prevent release of mesalazine
SULFASALAZINE,"Tablet: 0.5 g, 1 g; Suppository: 500 mg","Ulcerative colitis, active Crohn’s disease, active rheumatoid arthritis","Avoid in cases of hypersensitivity to salicylates or sulfonamides, child under 2 years, porphyria, intestinal or urinary obstruction, severe renal impairment. Use with caution in renal, hepatic impairment, G6PD deficiency, blood related disorder, child","Ulcerative colitis: adult (oral) - 1-2 g QID in acute attack until remission maintenance dose 500 mg QID, child > 2 yrs 40 -60 mg/kg in acute attack, reducing to maintenance dose 20-30 mg/kg daily; Active Crohn’s disease: adult (oral) 1-2 g QID in acute attack until omission occurs, child >2 year 40-60 mg/kg daily in acute attack; Ulcerative colitis, Crohn’s disease: by reactive suppositories, 0.5-1 g morning & evening after bowel movement, by rectum (retention enema), 3 gm at night for at least an hour","Nausea, vomiting, exacerbation of colitis, diarrhoea, loss of appetite, fever, blood disorders, hypersensitivity, lung complications (eosinophilia, fibrosing alveolitis), periorbital edema Patient information: Take each oral dose with full glass of water to prevent crystalluria, urine, skin may be coloured yellow orange.",
OCTREOTIDE,"Injection: 0.05 mg/ml, 0.1 mg/ml, 0.2 mg/ml, 0.5 mg/ml and 1 mg/ml","Esophageal variceal bleeding, acromegaly, carcinoid tumor, VIPoma","Esophageal variceal bleeding: 50 mcg IV bolus, then 25-50 mcg/hr for 1-5 days",,,
TERLIPRESSIN,Injection: 200 mg/2 ml,Bleeding from esophageal varices,"Avoid in seizure, migraine, asthma, heart failure and renal disease. Use in pregnant women only if clearly needed","Initially 2 mg every 4-6 hours until bleeding is controlled, then 1 mg every 4-6 hour for maximum up to 48 hours","Abdominal cramps, headache, cardiac arrhythmias",
URSODEOXYCHOLIC ACID,Tablets: 150 mg; Capsules: 250 mg,"Used in dissolution of gallstones, primary biliary cirrhosis","Pregnant and lactating mothers. Avoid aluminium containing antacids during therapy, may impair absorption","Dissolution of gall stones: 8-12 mg/kg daily as a single dose at bedtime or in two divided doses, for up to 2 years; treatment is continued for 3-4 months after stones dissolve; Primary biliary cirrhosis: 10-15 mg/kg daily in 2-4 divided doses","Nausea, vomiting, diarrhoea, gallstone calcification, pruritus",
GLYCERYL TRINATRE (Nitroglycerine),"Solution (infusion): 25 mg/250 ml, 50 mg/250
ml, 100 mg/250 ml; Solution (injection): 5 mg/ ml","Prophylaxis and acute attack of angina pectoris, Hypertensive
emergencies, acute decompensated heart failure","Avoid in hypersensitivity to nitrates,
hypotension, hypovolemia, hypertrophic obstructive cardiomyopathy,
aortic stenosis, cardiac tamponade, constrictive pericarditis, mitral stenosis,
marked anemia, head trauma, cerebral hemorrhage, angle-closure glaucoma.
Use caution in severe hepatic impairment, hypothyroidism, malnutrition,
hypothermia, recent history of myocardial infarction. Renal impairment: 10-
50 ml/min: never administer. Uninterrupted infusion > 24 hours produces
tolerance.","• Angina (acute attack): Intravenous infusion, adult: initially 5–10 mcg/min.
The rate of the infusion may be increased by 10 mcg/min every 3–5 min until
symptoms are relieved, systolic arterial pressure falls to <100 mm Hg, or the
dose reaches 200 mcg/min
• Hypertensive emergencies: Intravenous infusion, adult: 5-10 mcg/min
initial dose and up to 200 mcg/min as long as hemodynamic stability is
maintained) for the first 24–48 h after the onset of infarction.
• Acute decompensated heart failure: Intravenous infusion, adult: 10–20
mcg/min, increase up to 200 mcg/min. Intravenous infusion, Children:
Initially 0.25- 0.5 mcg/kg/min to titrate to 0.5-1.0 mcg/kg/min. Maximum
dose 20 mcg/kg/min
• Start with the lowest dose. Subsequent doses and intervals of administration
should be adjusted according to the blood pressure response and duration
of action.","Throbbing headache (most frequent in early therapy),
flushing, dizziness, postural hypotension, Tachycardia, syncope, paradoxical
bradycardia","Increases the effect of beta-blockers, ACE
inhibitors, angiotensin receptor blockers, calcium channel blockers. Avoid in
concomitant/recent use of erectile dysfunction products (sildenafil, tadalafil,
vardenafil) - may cause severe hypotension and death. Avoid alcohol intake."
ISOSORBIDE DINITRATE,"Tablet (sublingual): 5 mg, 10 mg","Prophylaxis and treatment of angina, left ventricular failure.","Avoid in hypersensitivity to nitrates,
hypotension, hypovolemia, hypertrophic obstructive cardiomyopathy,
aortic stenosis, cardiac tamponade, constrictive pericarditis, mitral stenosis,
marked anemia, head trauma, cerebral hemorrhage, angle-closure glaucoma.
Use caution in severe hepatic impairment, hypothyroidism, malnutrition,
hypothermia, recent history of myocardial infarction. Renal impairment: 10-
50 ml/min: never administer. Uninterrupted infusion > 24 hours produces
tolerance. Patients taking isosorbide dinitrate for the long-term management of angina
may often develop tolerance to the antianginal effect; avoid by giving the
second of 2 daily doses of longer-acting oral preparations after an 8-hour
rather than a 12-hour interval, thus ensuring a nitrate-free interval each day.","• Angina (acute attack): Sublingual, adult: 5–10 mg repeated as required.
• Angina (prophylaxis): Oral, adult: 30-120 mg daily in divided doses.
Intravenous infusion: 2-10 mg daily, maximum dose 20 mg/hour.
• Left ventricular failure: Oral, adult 40-160 mg daily in divided doses,
maximum dose 240 mg daily in divided doses. Intravenous infusion: 2-10
mg daily, maximum dose 20 mg/hour.","Throbbing headache (most frequent in early therapy),
flushing, dizziness, postural hypotension, Tachycardia, syncope, paradoxical
bradycardia, tolerance (in long term,
uninterrupted use)",
ATENOLOL,"Tablet: 25 mg, 50 mg, 100 mg; Solution: 500
mcg/ml in 10ml vial.","Chronic stable angina, secondary prevention after myocardial
infarction, supra ventricular arrhythmia, mild CHF, hypertension, migraine
prophylaxis.","Avoid in history of asthma or bronchospasm
(if no alternative, then use with extreme caution and under specialist
supervision), uncontrolled heart failure, prinzemetal angina, bradycardia
(heart rate <50 bpm), hypotension, sick sinus syndrome, second and third
degree atrioventricular block, cardiogenic shock, metabolic acidosis, severe
peripheral arterial disease, pheochromocytoma (unless used with an alpha
blocker). Use caution in patients with first –degree atrioventricular block,
portal hypertension, renal impairment (reduce dose), diabetes mellitus (small
decrease in glucose tolerance, which can mask symptoms of hypoglycemia),
history of hypersensitivity and myasthenia gravis, obstructive airway
disease, portal hypertension, psoriasis. Pregnancy- avoid (IUGR, neonatal
hypoglycemia and bradycardia). Breast feeding: avoid. Monitor lung function
in inadequate cardiac function and bronchospasm disease. Symptoms of
hypoglycemia and thyrotoxicosis may get masked. Assess weight daily, watch
for CHF (rales/crackles, jugular vein distension, weight gain, and edema).
Abrupt withdrawal of drug may exacerbate angina symptoms or precipitate
myocardial infarction in patients with coronary artery disease.","• Hypertension: Oral, adult: 25 – 50 mg daily. Oral, child: 0.5-1.0 mg/kg/dose
in 1-2 divided doses daily. Maximum dose- 2mg/kg/day or 100 mg/day
• Angina: Oral, adult: 100 mg, maximum dose 200 mg daily 1 or 2 doses.
• Arrhythmias: Oral, adult: 50-100 mg daily. Intravenous, adult: 2.5 mg at
rate of 1 mg/min repeated at 5 min interval to a maximum of 10 mg/dose.
Intravenous infusion, adult: 150 mcg/kg every 12 hourly over 20 minutes,
repeated every 12 hours if required.
• Early intervention Myocardial infarction (within 12 hour): slow intravenous
infusion, adult: 5 mg by then oral 50 mg after 15 minutes then oral 50 mg
after 12 hours then 100 mg daily.
• Migraine prophylaxis: Oral, adult: 50–200 mg daily in divided doses","Bradycardia, gastrointestinal disturbances including
nausea, vomiting, diarrhea, constipation, abdominal cramp, fatigue, cold
hands and feet, hypertriglyceridemia.","Avoid with verapamil. Hypotensive effect
increases with diuretics, ACE inhibitors, Angiotensin II receptor antagonist,
calcium channel blocker. Atenolol may enhance bradycardia produced by
cardiac glycosides."
BISOPROLOL,"Tablet: 2.5 mg, 5 mg, 10 mg","Hypertension, angina, adjunct in heart failure","Avoid in history of asthma or bronchospasm
(if no alternative, then use with extreme caution and under specialist
supervision), uncontrolled heart failure, prinzemetal angina, bradycardia
(heart rate <50 bpm), hypotension, sick sinus syndrome, second and third
degree atrioventricular block, cardiogenic shock, metabolic acidosis, severe
peripheral arterial disease, pheochromocytoma (unless used with an alpha
blocker). Use caution in patients with first –degree atrioventricular block,
portal hypertension, renal impairment (reduce dose), diabetes mellitus (small
decrease in glucose tolerance, which can mask symptoms of hypoglycemia),
history of hypersensitivity and myasthenia gravis, obstructive airway
disease, portal hypertension, psoriasis. Pregnancy- avoid (IUGR, neonatal
hypoglycemia and bradycardia). Breast feeding: avoid. Monitor lung function
in inadequate cardiac function and bronchospasm disease. Symptoms of
hypoglycemia and thyrotoxicosis may get masked. Assess weight daily, watch
for CHF (rales/crackles, jugular vein distension, weight gain, and edema).
Abrupt withdrawal of drug may exacerbate angina symptoms or precipitate
myocardial infarction in patients with coronary artery disease.","• Hypertension and angina: Oral, adult: 5-10 mg once daily, 20 mg daily
(maximum).
• Adjunct in heart failure: Oral, adult: initially 1.25 mg once daily (in the
morning) for 1 week then, if well tolerated, increased to 2.5 mg once daily
for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4
weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily, maximum
10 mg daily.","Bradycardia, gastrointestinal disturbances including
nausea, vomiting, diarrhea, constipation, abdominal cramp, fatigue, cold
hands and feet, hypertriglyceridemia.","Avoid with verapamil. Hypotensive effect
increases with diuretics, ACE inhibitors, Angiotensin II receptor antagonist,
calcium channel blocker. Atenolol may enhance bradycardia produced by
cardiac glycosides."
CARVEDILOL,"Tablet: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg","Angina, hypertension, adjunct to diuretics/digoxin/ACE
inhibitors in heart failure","Avoid in history of asthma or bronchospasm
(if no alternative, then use with extreme caution and under specialist
supervision), uncontrolled heart failure, prinzemetal angina, bradycardia
(heart rate <50 bpm), hypotension, sick sinus syndrome, second and third
degree atrioventricular block, cardiogenic shock, metabolic acidosis, severe
peripheral arterial disease, pheochromocytoma (unless used with an alpha
blocker). Use caution in patients with first –degree atrioventricular block,
portal hypertension, renal impairment (reduce dose), diabetes mellitus (small
decrease in glucose tolerance, which can mask symptoms of hypoglycemia),
history of hypersensitivity and myasthenia gravis, obstructive airway
disease, portal hypertension, psoriasis. Pregnancy- avoid (IUGR, neonatal
hypoglycemia and bradycardia). Breast feeding: avoid. Monitor lung function
in inadequate cardiac function and bronchospasm disease. Symptoms of
hypoglycemia and thyrotoxicosis may get masked. Assess weight daily, watch
for CHF (rales/crackles, jugular vein distension, weight gain, and edema).
Abrupt withdrawal of drug may exacerbate angina symptoms or precipitate
myocardial infarction in patients with coronary artery disease. Avoid in acute
decompensated heart failure requiring intravenous inotropes. Check for
edema in feet, legs daily. Rise slowly from sitting or lying position to minimize
orthostatic hypotension","• Hypertension: Oral, adult: Initially 12.5 mg once daily for 2 days, then
increased to 25 mg once daily; increased if necessary up to 50 mg daily,
dose to be increased at intervals of at least 2 weeks and can be given as a
single dose or in divided doses daily.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    • Angina: Oral, adult: initially 12.5 mg once daily, increased after 2 days to 25
mg twice daily.
• Adjunct in heart failure: Oral, adult: initially 3.125 mg twice daily to 6.25
mg twice daily, then to 12.5 mg twice daily then to 25 mg twice daily. Dose
increased at intervals of at least 2 weeks","Allergic skin reactions, angina, AV block, changes in
liver enzymes, depressed mood, disturbances of micturition, influenza-
like symptoms, leucopenia, nasal stuffiness, postural hypotension,
thrombocytopenia, wheezing, headache, dizziness, bradycardia and
impotence","Conduction disturbances increases with calcium
channel blocker. Carvedilol increases the effect of antidiabetic drugs."
METOPROLOL,"Tablets: 50 mg, 100 mg; Injection: 1 mg/ml","Angina, hypertension, arrhythmias, migraine prophylaxis,
hyperthyroidism adjunct, early intervention in myocardial infarction.","Avoid in history of asthma or bronchospasm
(if no alternative, then use with extreme caution and under specialist
supervision), uncontrolled heart failure, prinzemetal angina, bradycardia
(heart rate <50 bpm), hypotension, sick sinus syndrome, second and third
degree atrioventricular block, cardiogenic shock, metabolic acidosis, severe
peripheral arterial disease, pheochromocytoma (unless used with an alpha
blocker). Use caution in patients with first –degree atrioventricular block,
portal hypertension, renal impairment (reduce dose), diabetes mellitus (small
decrease in glucose tolerance, which can mask symptoms of hypoglycemia),
history of hypersensitivity and myasthenia gravis, obstructive airway
disease, portal hypertension, psoriasis. Pregnancy- avoid (IUGR, neonatal
hypoglycemia and bradycardia). Breast feeding: avoid. Monitor lung function
in inadequate cardiac function and bronchospasm disease. Symptoms of
hypoglycemia and thyrotoxicosis may get masked. Assess weight daily, watch
for CHF (rales/crackles, jugular vein distension, weight gain, and edema).
Abrupt withdrawal of drug may exacerbate angina symptoms or precipitate
myocardial infarction in patients with coronary artery disease. Abrupt withdrawal
may cause MI, ventricular arrhythmias, myocardial ischemia; taper dose over
7-14 days.","• Angina: Oral, adult: 50- 100 mg, 2-3 times daily.
• Hypertension: Oral, adult: initially 100 mg daily, maximum dose 400 mg
daily in 1-2 doses.
• Arrhythmias: Oral, adult: 50-100 mg, 2-3 times daily, maximum dose 300
mg daily in divided doses. Intravenous, adult: up to 5 mg at rate 1-2 mg/
minute repeated after 5 minutes if necessary, total dose 10-15 mg.
• Migraine prophylaxis: Oral, adult: 100 -200 mg daily in divided doses.
• Early intervention in myocardial infarction (within 12 hours): Intravenous,
adult: 5 mg every 2 minutes to a maximum dose of 15 mg, followed after 15
minutes by oral 50 mg every 6 hours for 48 hours; maintenance oral 200 mg
daily in divided doses.
• Hyperthyroidism (adjunct): Oral, adult: 50 mg 4 times a day
• In surgery: intravenous 2-4 mg by slow injection to control arrhythmias
developing during anesthesia; 2 mg doses may be repeated, maximum dose
10 mg.
• Oral, child: 1-2 mg/kg/day in 2 divided doses daily. Maximum dose 6 mg/
kg/day up to 200 mg/day
Assess ECG directly when giving IV during initial treatment.","Bradycardia, gastrointestinal disturbances including
nausea, vomiting, diarrhea, constipation, abdominal cramp, fatigue, cold
hands and feet, hypertriglyceridemia.","Avoid with verapamil. Hypotensive effect
increases with diuretics, ACE inhibitors, Angiotensin II receptor antagonist,
calcium channel blocker. Atenolol may enhance bradycardia produced by
cardiac glycosides."
PROPRANOLOL,"Tablet: 10 mg, 20 mg, 40 mg, 80 mg. Injection:
1 mg/ml","Chronic stable angina, hypertension, secondary prevention after
acute myocardial infraction, anxiety, thyrotoxicosis, migraine prophylaxis,
pheochromocytoma (only with alpha blocker), prophylaxis of variceal
bleeding in portal hypertension, hypertrophic obstructive cardiomyopathy,
mitral valve prolapse, essential tremor, child with cyanotic spells or
hypertension or infantile hemangioma","Avoid in history of asthma or bronchospasm
(if no alternative, then use with extreme caution and under specialist
supervision), uncontrolled heart failure, prinzemetal angina, bradycardia
(heart rate <50 bpm), hypotension, sick sinus syndrome, second and third
degree atrioventricular block, cardiogenic shock, metabolic acidosis, severe
peripheral arterial disease, pheochromocytoma (unless used with an alpha
blocker). Use caution in patients with first –degree atrioventricular block,
portal hypertension, renal impairment (reduce dose), diabetes mellitus (small
decrease in glucose tolerance, which can mask symptoms of hypoglycemia),
history of hypersensitivity and myasthenia gravis, obstructive airway
disease, portal hypertension, psoriasis. Pregnancy- avoid (IUGR, neonatal
hypoglycemia and bradycardia). Breast feeding: avoid. Monitor lung function
in inadequate cardiac function and bronchospasm disease. Symptoms of
hypoglycemia and thyrotoxicosis may get masked. Assess weight daily, watch
for CHF (rales/crackles, jugular vein distension, weight gain, and edema).
Abrupt withdrawal of drug may exacerbate angina symptoms or precipitate
myocardial infarction in patients with coronary artery disease. Use caution in
inadequate cardiac function and bronchospastic disease. Reduce oral
dose in renal and hepatic impairment. Pregnancy (C) breast feeding: safety
not established. Do not discontinue abruptly; as dysrhythmia, angina,
myocardial ischemia may occur so taper over at least a few weeks. Symptoms
of hypoglycemia may get masked- monitor blood glucose.","• Hypertension: Oral, adult: initially 80 mg twice daily, increased at weekly
intervals as required; maintenance dose 160-320 mg daily. Oral, child: 1-4
mg/kg/day in 3-4 divided doses.
• Prophylaxis of variceal bleeding in portal hypertension: Oral, adult: initially
40 mg twice daily increased to 80 mg twice daily according to heart rate;
maximum dose 160 mg twice daily.
• Pheochromocytoma (only with an alpha blocker): Oral, adult: 60 mg daily
for 3 days before surgery. 30 mg daily for patients not fit for surgery
• Angina: Oral, adult: initially 40 mg 2-3 time daily; maintenance 120-240 mg
daily.
• Arrhythmias, hypertrophic obstructive cardiomyopathy, anxiety,
tachycardia and thyrotoxicosis (adjunct): Oral, adult: 10-40 mg in 3-4
divided doses daily
• Anxiety (with symptoms such as palpitation, sweating, tremor): Oral, adult:
40 mg once daily; may increase to 40 mg 3 times daily, if necessary.
• Prophylaxis after infraction: Oral, adult: 40 mg 4 times daily for 2-3 days,
then 80 mg twice daily, beginning 5-21 days after infraction.
• Essential tremor: Oral, adult: initially 40 mg 2-3 times daily; maintenance
80-160 mg daily.
• Migraine prophylaxis: Oral, adult: 80-240 daily divided doses.
• Arrhythmias and thyrotoxic crisis: Intravenous injection; 1 mg over 1 minute.
• Cyanotic spells: Child, intravenous: 0.15-0.25 mg/kg/day in 4 divided dose,
not to exceed 1 mg for infants and 3 mg for children. Oral, child: 2-4 mg/kg/
day in 4 divided doses
• Infantile hemangioma: Oral, child: 1-2 mg/kg/day in 3 divided doses","Bradycardia, gastrointestinal disturbances including
nausea, vomiting, diarrhea, constipation, abdominal cramp, fatigue, cold
hands and feet, hypertriglyceridemia. Hallucination, nightmare, sexual
dysfunction.","Avoid with verapamil. Hypotensive effect
increases with diuretics, ACE inhibitors, Angiotensin II receptor antagonist,
calcium channel blocker. Atenolol may enhance bradycardia produced by
cardiac glycosides. Hypersensitivity to
catecholamine during withdrawal"
DILTIAZEM,"Tablet: 30 mg, 60 mg",Angina pectoris,"Avoid in acute porphyria, left ventricular
failure with pulmonary congestion, second- or third-degree AV block (unless
pacemaker fitted), severe bradycardia, sick sinus syndrome. Use caution
bradycardia (avoid if severe), first degree AV block, heart failure, prolonged
PR interval, significantly impaired left ventricular function. Pregnancy: avoid.
Hepatic impairment reduce dose. Renal impairment, start with smaller dose.","• Angina: Oral, adult: Initially 60 mg 3 times a day, adjusted according to
response; maximum 360 mg/day. Elderly: Initially 60 mg twice daily,
adjusted according to response; maximum 360 mg per day
• Oral, child: 1.5-2 mg/kg/day in 3-4 divided doses (maximum dose: < 6mg/
kg/day up to 360 mg/day","Asthenia, AV block, bradycardia, dizziness, gastro-intestinal
disturbances, headache, hot flushes, hypotension, malaise, edema (notably
of ankles), palpitation, Sino-atrial block",
VERAPAMIL,"Verapamil Hydrochloride: Tablet (immediate
release): 40 mg, 80 mg, 240 mg. Solution: 2.5 mg/ml
Verapamil injection should be protected from light.","Angina pectoris, supra ventricular arrhythmias, hypertension,
migraine prophylaxis, supraventricular tachycardia in children","Hypotension, bradycardia, second- and
third-degree heart block, sick sinus syndrome; cardiogenic shock, history
of heart failure , atrial flutter or fibrillation complicating Wolff-Parkinson-
White syndrome, acute porphyria. First-degree atrioventricular block, acute
phase of myocardial infarction (avoid if bradycardia, hypotension, or left
ventricular failure present), hepatic impairment; children (specialist advice
only); Pregnancy and breastfeeding: Avoid use in neonate and young infants.
Not to discontinue abruptly, chest pain may occur.","• Angina, supraventricular arrhythmia: Oral, adult: 40-120 mg 3 times daily
• Hypertension: Oral, adult: 240-480 mg daily in 2- 3 divided doses. By
slow intravenous injection over 2 minutes (3 minutes in elderly), 5 - 10 mg
(preferably with ECG monitoring)
• Paroxysmal tachyarrhythmia: slow intravenous injection, adult: initially
5-10 mg further 5 mg after 5-10 minutes if required over 2 minutes (over 3
minutes in elderly) under ECG monitoring.
• Supraventricular tachycardia: Child, intravenous: 0.1-0.3 mg/kg/dose may
be repeated in 30 min. Maximum first dose 5 mg, and second dose 10 mg
• Supraventricular arrhythmias: slow intravenous injection, adult: 5-10 mg,
over 2 minutes (over 3 minutes in elderly) under ECG monitoring","Constipation; less commonly nausea, vomiting, flushing,
headache, dizziness, fatigue, and ankle edema; rarely allergic reactions
including pruritus, urticaria, angioedema, and erythema multiforme (Stevens-
Johnson syndrome); myalgia, arthralgia, paresthesia, erythromelalgia;
increased prolactin concentration; gynecomastia and gingival hyperplasia
on long-term treatment; hypotension, heart failure, bradycardia, heart block,
and asystole (due to negative inotropic effect) with high doses.",
ADENOSINE,Injection: 6 mg/2 ml vial,"Paroxysmal supraventricular tachycardia (including Wolff-
Parkinson-White syndrome)","Pre-existing second or third degree AV
block, asthma and sick sinus syndrome. Use cautiously in arterial fibrillation
or flutter and heart transplant.","• Rapid intravenous injection into central or large peripheral vein: 3 mg over
2 seconds with cardiac monitoring; if necessary followed by 6 mg after 1-2
minutes and then by 12 mg after a further 1-2 minutes.
• Neonate, intravenous: 0.05 mg/kg over 1-2 sec may increase dose by 0.05
mg/kg every 2 mins. Maximum dose 0.25 mg/kg
• Child, intravenous: 0.1-0.2 mg/kg (initial maximum dose 6 mg) over 1-2 sec.
May increase dose by 0.05mg/kg every 2 mins to maximum of 0.25 mg/kg
Follow each dose with normal saline flush. Assess the cardiopulmonary and
respiratory status.","Chest pain, transient facial flush, bronchospasm,
nausea and severe bradycardia, difficult or labored breathing, chest tightness","Increased risk for higher degree of heart
block: carbamazepine. Increased risk of ventricular fibrillation with digoxin,
verapamil. Increased effects with dipyridamole. Methylxanthines decrease
the activity of adenosine
Patient’s information: Patient should report facial flushing, dizziness,
sweating, palpitations, and chest pain (usually transient)."
AMIODARONE,"Tablet: 100 mg, 200 mg; Solution: 25 mg/ml, 30
mg/ml, 50 mg/ml","Paroxysmal supraventricular, nodal and ventricular tachycardia,
atrial fibrillation or flutter, ventricular arrhythmia (unresponsive to others)
and ventricular fibrillation, all atrial and ventricular tachycardia","Avoid in sinus bradycardia, SA heart block,
Iodine sensitivity, cardiogenic shock, second or third degree AV block, thyroid
dysfunctions, severe hepatic, pneumonitis, pulmonary fibrosis, hypokalemia,
CHF (with inadequate compensation). Pregnancy: risk of neonatal goiter.
Breast feeding: avoid. Clinical monitoring (baseline and every 3 to 6 months)
of serum potassium; chest X-ray, pulmonary function tests (with diffusion
capacity), liver function test and thyroid function tests is recommended.
Toxicity is reversible when managed early.","• Arrhythmias: Oral, adult: 200 mg 3 times daily for 1 week reduced to 200
mg twice daily
• Ventricular fibrillation: intravenous infusion, adult: 300 mg over at least 3
minutes.
• Drug resistant refractory cardiac arrhythmia: Oral, child: < 1 year: 600-
800 mg/1.73m2/day in 1-2 divided dose for 1-14 days. > 1 years: 10-15 mg/
kg/day in 1-2 divided doses for -14 days and/or until adequate control is
achieved, then reduce to 5 mg/kg/day. Child, intravenous: 5 mg/kg over 30
min followed by continuous infusion at the rate of 5 mcg/kg/min. Maximum
dose: 15 mcg/kg/min or 20 mg/kg/day
• Infusion should be diluted in glucose 5%, concentration should not exceed
2 mg/ml.
Marked hypotension on IV administration.","Nausea, vomiting, raised serum transaminases,
bradycardia, ventricular arrhythmia, ventricular fibrillation. Neurologic
dysfunction (dizziness, paresthesia, tremor and involuntary movements, lack
of co-ordination, abnormal gait and ataxia), thyroid dysfunction, pulmonary
toxicity (pneumonitis and fibrosis) on long term use.","Inhibits CYP450 enzymes and may increase
concentrations of Digoxin, Methotrexate, Theophylline, Procainamide.
Increase risk of myopathy with simvastatin. Increased risk of bradycardia with
beta-blockers, calcium channel blockers. Increased risk of QT prolongation
with azoles, fluoroquinolones, macrolides
Patient’s information: Do not discontinue abruptly. Use sunscreen or stay
out of sun to prevent burns, use dark glasses to prevent photophobia. Skin
discoloration is usually reversible"
DIGOXIN,"Injection: 250 mcg/ml in 2-ml ampoule; Oral liquid: 50
mcg/ml; Tablet: 62.5 mcg, 250 mcg","Supraventricular arrhythmias, particularly atrial fibrillation;
heart failure
(considered for selected patients who remain symptomatic despite treatment
with an ACE inhibitor, a diuretic, and a suitable beta-blocker)","Avoid in hypertrophic obstructive
cardiomyopathy (unless also atrial fibrillation and heart failure); Wolff-
Parkinson-White syndrome or other accessory pathway, particularly if
accompanied by atrial fibrillation; ventricular tachycardia or fibrillation;
intermittent complete heart block; second-degree atrioventricular block.
Use caution in recent myocardial infarction; sick sinus syndrome; severe
Pulmonary disease; thyroid disease; the elderly (reduce dose); renal
impairment; avoid hypokalemia; avoid rapid intravenous administration
(nausea and increased risk of arrhythmias); Pregnancy (C) Breastfeeding:
use with caution. Obtain ECG after 6 hours to assess toxicity. Monitor apical
pulse for 1 full minute before administration .Withhold dose if pulse rate is
<60 bpm in an adult, <70 bpm is a child or <90 bpm in an infant. Monitor
blood pressure periodically, monitor ECG throughout IV administration and
6 hrs. after each dose. Therapeutic drug monitoring is advised in patient
receiving digoxin. Take missed doses within 12 hrs. of scheduled dose. Do
not double the dose.
Digoxin has been associated with an increased risk of falls in the elderly, so
patient and family should be advised for monitoring.","• Atrial fibrillation: Oral, adult: initially 1–1.5 mg in divided doses over 24
hours for rapid digitalization (or 250 mcg once or twice daily if digitalization
less urgent) followed by: 62.5–500 mcg daily (higher dose may be divided),
according to renal function and heart rate response; usual maintenance
dose: 125–250 mcg daily (lower dose more appropriate in the elderly).
• Emergency control of atrial fibrillation: intravenous infusion over at least 2
hours, adult: 0.75–1 mg.
NOTE. Infusion dose may need to be reduced if digoxin or other cardiac
glycoside has been given in previous 2 weeks.","Usually only with high doses; gastrointestinal disturbances
including anorexia, nausea, vomiting, diarrhea, and abdominal pain; visual
disturbances, headache, fatigue, drowsiness, confusion, dizziness, delirium,
hallucinations, depression; all arrhythmias except for rapidly conducted
atrial arrhythmias (atrial fibrillation and atrial flutter) and except Mobitz
type II second degree heart block; rarely rash, and intestinal ischemia;
gynecomastia on long-term use; thrombocytopenia reported.","When digoxin is administered with beta
blockers and verapamil, there is increased risk of AV block and bradycardia."
DISOPYRAMIDE,"Capsules: 100 mg, 150 mg; Injection: 10 mg in
5 ml ampoule.","Atrial and ventricular arrhythmias including those resistant to
lignocaine.","Avoid in preexisting second or third degree
AV block, cardiogenic shock, heart failure (can produce severe hypotension
due to negative inotropic properties). Renal or hepatic insufficiency, third
trimester of pregnancy, glaucoma, myasthenia gravis or urinary retention.
Use caution in the elderly and children because they may be more sensitive
to its effects.","Oral (immediate release), adult: 300-800 mg daily in
divided doses. Slow intravenous injection, adult: 2 mg/kg over at least 5
minutes to a maximum of 150 mg with ECG monitoring.
Take disopyramide on a regular schedule around the clock, unless otherwise directed by your doctor. If you miss a dose of disopyramide, take it if you
remember within 4 hours. If it has been more than 4 hours since your missed
dose, skip the missed dose and go back to your regular doses schedule. Do
not take 2 doses at once.","Angle-closure glaucoma, antimuscarinic effects, AV block,
blurred vision, cholestatic jaundice, dry mouth, gastro-intestinal irritation,
hypoglycemia, hypotension, myocardial depression, psychosis, urinary
retention, ventricular tachycardia, ventricular fibrillation or torsade de
pointes (usually associated with prolongation of QRS complex or QT interval).","The effects of disopyramide can increase with
metoprolol and alcohol (minor).
Patient’s information: Do not drive, operate machinery. Do not stop the drug
suddenly."
ISOPRENALINE,Injection: 0.2 mg/ml. Tablet: 20 mg,"Torsade de pointes, bradycardia in patients with heart block,
control attacks of Stokes Adam syndrome.","Preexisting cardiac arrhythmia (especially
tachycardia).","• Intravenous injection, adult: 0.5-10 mcg/minute
• Oral, adult: initially 30 mg every 6hours, range, 90-840 mg daily (but oral
route is rarely used).","Tachycardia, hypotension, arrhythmia, tremor, sweating",
LIDOCAINE/ LIGNOCAINE,Injection: 20 mg/ml in 5 ml ampoule,"Ventricular arrhythmias (especially after myocardial infarction),
local anesthesia","Avoid in Sino atrial nodal disorder, any
grade of atrioventricular block or any other type of conduction disturbances,
severe myocardial depression, acute porphyria or hypovolemia, Wolff-
Parkinson-White syndrome, Stokes Adams syndrome. Lower dosage
in congestive heart failure and following cardiac surgery, bradycardia,
hepatic impairment, severe respiratory depression, the elderly, pregnancy
and breastfeeding, hypothermia, electrolyte imbalance (potassium and
magnesium imbalance). Monitor for ECG","• Ventricular arrhythmias: intravenous injection, adult: loading dose of 50-
100 mg (or 1-1.5 mg/kg) at a rate of 25-50 mg/minute, followed immediately
by intravenous infusion of 1-4 mg/minute, with ECG monitoring of all
patients (reduce infusion dose if required for longer than 24 hours).
• Intravenous, child: 1 mg/kg/dose slow IV, may repeat 10-15 min. Maximum
total dose: 3-5 mg/kg within first hour.
Lidocaine has a short duration of action (15-20 minutes), if the intravenous
infusion cannot be given immediately, the initial intravenous injection of 50-
100 mg can be repeated once or twice at intervals of not less than 10 minutes.","Flushing or redness, dizziness, paresthesia, itching,
drowsiness, confusion, apnea, respiratory depression, coma, seizure and
convulsions, hypotension, arrhythmia, heart block, cardiovascular collapse,
bradycardia (may lead to cardiac arrest), nystagmus (often an early sign of
lidocaine overdose).","Increased cardiac depression and toxicity with
amiodarone, phenytoin, procainamide, propranolol. Increased neuromuscular
blockade with neuromuscular blockers. Increased hypotensive effects with
MAO inhibitors, antihypertensive. Increased effects of lorazepam (additive
CNS depressants) and alprazolam effects (increase CNS side effects)"
PROCAINAMIDE,"Solution: 100 mg /ml in 10 ml ampoule; tablet:
250 mg","Severe ventricular arrhythmias (especially those resistant to
lidocaine or those appearing after myocardial infarction); atrial tachycardia,
atrial fibrillation; maintenance of sinus rhythm after cardioversion of atrial
fibrillation.","Avoid in Torsade’s de pointes, SLE, 2nd and
3rd degree heart block, heart failure, hypotension, elderly, renal impairment,
hepatic impairment, asthma, myasthenia gravis, pregnancy, breastfeeding,
electrolyte imbalance (hyperkalemia, hypokalemia, magnesium disorders).
Discontinue treatment in case of drop in leukocyte and platelet count.
Perform complete blood count twice a week for 3 months.","• Oral, adult:, up to 50 mg/kg daily in divided doses every 3-6 hours, preferably
controlled by monitoring plasma-procainamide concentration (therapeutic
concentration usually within 3-10 mcg/ml); in atrial arrhythmia, higher
doses may be required.
• Slow intravenous injection, adult: rate not exceeding 50 mg/minute, 100
mg repeated at 5 minute intervals until arrhythmia controlled; maximum 1g.
• Intravenous infusion, adult: 500-600 mg over 25-30 minutes, followed
by maintenance at rate of 2-6 mg/minute, then if necessary oral anti-
arrhythmic treatment as above, starting 3-4 hours after infusion.
When using IV, monitor continuously by ECG.","Nausea, vomiting, diarrhea, anorexia, rash, pruritus,
urticarial, flushing, fever, myocardial depression, heart failure, angioedema,
depression, dizziness, psychosis; blood disorders including leukopenia,
hemolytic anemia and agranulocytosis after prolonged treatment, SLE like
syndrome, high plasma procainamide concentration may impair cardiac
conduction.
Patient’s information: A wax matrix may appear in stools. Do not discontinue
without prescriber’s approval. Notify prescriber if lupus-like symptoms
appear, leucopenia (sore mouth, gums, and throat) or thrombocytopenia,
bleeding, bruising). Avoid driving until product effect is known",
CAPTOPRIL,"Tablet: 25 mg, 50 mg","Mild to moderate essential hypertension, adjunctive treatment
in congestive heart failure, severe hypertension resistant to other treatment,
following myocardial infraction, diabetic nephropathy in insulin dependent
diabetes.","Avoid in bilateral renal artery stenosis,
pregnancy, hyperkalemia, pre-existing cough. Use caution in severe or
symptomatic aortic stenosis. Monitor renal function before and during
treatment.","Hypertension: Oral, adult: initially 5 mg once daily, lower
initial dose if used in addition to diuretic or in renal impairment; usual
maintenance dose 20 mg once daily; maximum 40 mg once daily. Take 1-2
hours after meals.","alopecia, rash, profound hypotension (usually with first
dose, especially in patients taking high dose of diuretics on low sodium
diet, dehydration, taste impairment, leucopenia, proteinuria, persistent dry
cough, sleep disorder, dyspnea, pallor, neutropenia, Raynaud’s syndrome.","With potassium sparing diuretics hyperkalemia
may result especially in existing renal impairment. With alcohol, alpha
blocker, general anesthetic, angiotensin 2 receptor antagonist, beta blocker,
calcium channel blocker, hypotensive effect is increased.
Patient’s information: Avoid activities that require concentration, the person
may feel dizziness, fainting, and light headedness. Not to discontinue
product abruptly, if dose is missed, take as soon as remembered but do not
double the doses. Rise slowly to sitting or standing position to minimize
orthostatic hypotension"
ENALAPRIL,"Tablets: 2.5 mg, 5 mg, 10 mg","Hypertension, heart failure","Avoid in bilateral renal artery stenosis,
pregnancy, hyperkalemia, pre-existing cough. Use caution in severe or
symptomatic aortic stenosis. Monitor renal function before and during
treatment. Avoid in renal
impairment when GFR < 30 ml/1.73m2/min. use cautious in impaired liver
function and neonates. Monitor renal function.","• Hypertension: Oral, adult: 5 mg once daily, if used in addition to diuretic or
in renal impairment or in elderly patient, 2.5 mg daily initially, maintenance
dose 20 mg once daily: maximum 40 mg once daily. Oral, child: 0.1- 0.6 mg/
kg/day in 1-2 divided doses. Maximum dose 40 mg/day","Dizziness, headache, nausea, diarrhea, dry cough,
fatigue, asthenia, angioedema, urticaria, rashes, hyperkalemia, impaired
perspiration","With potassium sparing diuretics hyperkalemia
may result especially in existing renal impairment. With alcohol, alpha
blocker, general anesthetic, angiotensin 2 receptor antagonist, beta blocker,
calcium channel blocker, hypotensive effect is increased.
Patient’s information: Avoid activities that require concentration, the person
may feel dizziness, fainting, and light headedness. Not to discontinue
product abruptly, if dose is missed, take as soon as remembered but do not
double the doses. Rise slowly to sitting or standing position to minimize
orthostatic hypotension.  Patient’s information: Avoid activities requiring coordination, the drug may
cause skin rash, or angioedema. Discontinue if angioedema occurs. Patient’s information: Avoid activities requiring coordination, the drug may
cause skin rash, or angioedema. Discontinue if angioedema occurs."
LISINOPRIL,"Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg","Essential and renovascular hypertension, adjunctive treatment
in congestive heart failure, following myocardial infarction in hemodynamically
stable patients, diabetic nephropathy in normotensive insulin-dependent
and hypertensive non-insulin dependent diabetes mellitus.","Avoid in pregnancy, hereditary
angioedema, breast-feeding. Avoid in bilateral renal artery stenosis,
pregnancy, hyperkalemia, pre-existing cough. Use caution in severe or
symptomatic aortic stenosis. Monitor renal function before and during
treatment.","• Hypertension: initially 10 mg daily, if used in addition to diuretic or in
patient with renal impairment, initially 2.5-5 mg daily; usual maintenance
dose 20 mg once daily( maximum 80 mg daily).
• Heart failure (adjunct): Oral, adult: initially 2.5 mg daily; usual maintenance
dose 5-20 mg daily.
• Diabetic nephropathy: Oral, adult: initially 2.5 mg daily adjusted to achieve
diastolic blood pressure below 75 mm Hg in normotensive insulin dependent
diabetes and below 90 mm Hg in hypertensive non-insulin dependent
diabetes; usual dose range 10-20 mg daily.
• Prophylaxis after myocardial infarction: Oral, adult: 5 mg within 24 hours if
systolic blood pressure over 120 mm Hg, followed by further 5 mg 24 hours
later, then 10 mg after a further 24 hours, and continuing with 10 mg once
daily for 6 weeks; if systolic blood pressure 100-120 mm Hg, initially 2.5 mg,
increasing to maintenance dose of 5 mg once daily.","Profound hypotension, hyperkalemia, rash, tachycardia,
myocardial infarction, sweating, impotence, dizziness, upper respiratory tract
infection, fatigue, diarrhea.
Patient’s information: Drink plenty of water each day while taking the
medication. Avoid potassium rich diet.",
RAMIPRIL,"Tablets/Capsules: 1.25 mg, 2.5 mg, 5 mg, 10 mg","Hypertension, congestive heart failure, prophylaxis after
myocardial infarction, prophylaxis of cardiovascular events or stroke.","Avoid in pregnancy, hereditary
angioedema, breast-feeding. Avoid in bilateral renal artery stenosis,
pregnancy, hyperkalemia, pre-existing cough. Use caution in severe or
symptomatic aortic stenosis. Monitor renal function before and during
treatment.","• Hypertension: Oral, adult: initially 1.25 mg once daily, increased at intervals
of 1-2 weeks; usual range 2.5-5 mg once daily; maximum 10 mg once daily.
• Congestive heart failure (adjunct): Oral, adult: initially 1.25 mg once daily
under close medical supervision, increased if necessary at intervals of 1-2
weeks; maximum 10 mg daily.
• Prophylaxis after myocardial infarction: Oral, adult: initially 2.5 mg twice
daily, increased after 2 days to 5 mg twice daily; maintenance 2.5-5 mg
twice daily.
• Prophylaxis of cardiovascular events or stroke: initially 2.5 mg once daily,
increased after 1 week to 5 mg once daily, then increased after a further 3
weeks to 10 mg once daily.","Dizziness, headache, nausea, diarrhea, dry cough,
fatigue, asthenia, angioedema, urticaria, rashes, hyperkalemia, impaired
perspiration",
IRBESARTAN,"Tablet: 75 mg, 150 mg","Hypertension, hypertension in patients receiving hemodialysis,
renal disease in hypertensive with type 2 diabetes mellitus","Avoid in renal artery stenosis, moderate to
severe renal impairment or liver impairment, aortic or mitral valve stenosis.","• Hypertension: Oral, adult (18–74 years): Initially 150 mg once daily,
increased if necessary to 300 mg once daily.
• Hypertension: Oral, adult (>75 years): Initially 75–150 mg once daily,
increased if necessary to 300 mg once daily.
• Hypertension in patients receiving hemodialysis: Oral, adult: Initially 75–
150 mg once daily, increased if necessary to 300 mg once daily.
• Renal disease in hypertensive type 2 diabetes mellitus: Oral, adult (18–74
years): Initially 150 mg once daily, increased if tolerated to 300 mg once
daily.
• Renal disease in hypertensive type 2 diabetes mellitus: Oral, adult (>75
years): Initially 75–150 mg once daily, increased if tolerated to 300 mg once
daily","Fatigue, musculoskeletal pain, nausea, vomiting",
LOSARTAN,"Tablet: 25 mg, 50 mg","Hypertension, congestive heart failure, diabetic nephropathy in
type 2 diabetes mellitus","Avoid in pregnancy and breast feeding,
children of 6 years or younger, CHF, renal impairment (GFR < 30 ml/
min/1.73m2, renal artery stenosis. Use caution in moderate to severe renal
impairment or liver impairment, aortic or mitral valve stenosis.","• Hypertension: Oral, adult: 50 mg (in intravascular volume depletion initially/
elderly >75 years: initially 25 mg) once daily for several weeks, then increase
up to 150 mg in weekly interval if necessary and tolerated. Oral, Child: 0.75
mg/kg/dose once daily up to 50 mg/day. Maximum dose: 1.4 mg/kg/day or
100 mg/day
• Diabetic nephropathy in DM type II: Oral, adult: initially 50 mg (elderly >75
years: 25 mg) once daily for several weeks then increase up to 100 mg in
weekly interval if necessary and tolerated.
• CHF with ACE inhibitors unsuitable or contraindicated: Oral, adult: Initially
12.5 mg once daily, increase if tolerated to up to 150 mg once daily, to be
increased daily.","Hypotension, dizziness, diarrhea, pruritus, rash, taste
disturbance, thrombocytopenia, photosensitivity","With lithium, increases lithium toxicity. With
hypertensive agents, increases antihypertensive effect. Avoid use in Aliskiren.
Patient’s information: Rise slowly to sitting or standing position to minimize
orthostatic hypotension. Avoid sunlight, salt substitutes, alcohol, over the
counter products unless approved by prescriber."
TELMISARTAN,"Tablet: 20 mg, 40 mg, 80 mg","Hypertension, prevention of cardiovascular events in patients
with established atherosclerotic cardiovascular disease or type 2 diabetes
mellitus with target-organ damage.","Avoid in bilateral renal artery stenosis, pregnancy and
breast feeding, in severe impairment or biliary obstruction.","• Hypertension: Oral, adult: Initially 20–40 mg once daily for at least 4 weeks,
increased if necessary up to 80 mg once daily
• Prevention of cardiovascular events in patients with established
atherosclerotic cardiovascular disease or type 2 diabetes mellitus with
target-organ damage: Oral, adult: 80 mg once daily
• Severe renal impairment: Oral, adult: Initial dose of 20 mg once daily.","Arthralgia, back pain, chest pain, eczema, gastro-intestinal
disturbances, influenza like symptoms, leg cramps, myalgia, pharyngitis,
sinusitis, urinary-tract infection, abnormal vision, anxiety, dry mouth,
increased sweating, tendonitis- like symptoms, vertigo","Avoid use with ACE inhibitor, aspirin, acebutolol,
aceclofenac, amiloride, atenolol, chlorthiazide, digoxin, enoxaparin,
furosemide, ibuprofen, insulin, irbesartan, ketorolac, piroxicam, potassium
chloride, spironolactone, sulfasalazine, torsemide, trimethoprim."
VALSARTAN,"Tablet: 40 mg, 80 mg, 160 mg","Hypertension, myocardial infarction with left ventricular failure
or left ventricular systolic dysfunction.","Avoid in pregnancy and breast feeding,
children of 6 years or younger, CHF, renal impairment (GFR < 30 ml/
min/1.73m2, renal artery stenosis. Use caution in moderate to severe renal
impairment or liver impairment, aortic or mitral valve stenosis. Avoid in biliary
cirrhosis, cholestasis, severe hepatic impairment, renal impairment when
eGFR <10 ml/min/ 1.73m2. Use caution in mild to moderate renal and hepatic
impairment.","• Hypertension: Oral, adult: 80 mg once daily (initially 40 mg once daily in
intravascular volume depletion); if necessary increased after at least 4
weeks to 160 mg daily.
• Myocardial infarction: Oral, adult: initially 20 mg twice daily increased over
several weeks to 160 mg twice daily if tolerated.
• Mild to moderate hepatic impairment: maximum dose of 80 mg daily.
Take medicine before meal.","Hypotension, dizziness, diarrhea, pruritus, rash, taste
disturbance, thrombocytopenia, photosensitivity",Food interferes with absorption.
LABETALOL,"Tablet: 100 mg, 200 mg; Solution: 100 mg/20ml","Hypertension, Hypertensive emergencies, hypertension
following myocardial infarction, hypertension of pregnancy","Avoid in severe liver damage. Hepatic
impairment: avoid as reported. Renal impairment: Dose reduction may be
required. Pregnancy: possibly harmful in the first trimester. If labetalol used
close to delivery, monitor infants for signs of alpha-blockade (as well as beta
blockade). Breast feeding: monitor infants for possible toxicity due to alpha-
blockade (in addition to beta-blockade. Laboratory testing needed at first
symptom of liver dysfunction and if laboratory evidence of damage (or if
jaundice) labetalol should be stopped and not restarted. Avoid in history of asthma or bronchospasm
(if no alternative, then use with extreme caution and under specialist
supervision), uncontrolled heart failure, prinzemetal angina, bradycardia
(heart rate <50 bpm), hypotension, sick sinus syndrome, second and third
degree atrioventricular block, cardiogenic shock, metabolic acidosis, severe
peripheral arterial disease, pheochromocytoma (unless used with an alpha
blocker). Use caution in patients with first –degree atrioventricular block,
portal hypertension, renal impairment (reduce dose), diabetes mellitus (small
decrease in glucose tolerance, which can mask symptoms of hypoglycemia),
history of hypersensitivity and myasthenia gravis, obstructive airway
disease, portal hypertension, psoriasis. Pregnancy- avoid (IUGR, neonatal
hypoglycemia and bradycardia). Breast feeding: avoid. Monitor lung function
in inadequate cardiac function and bronchospasm disease. Symptoms of
hypoglycemia and thyrotoxicosis may get masked. Assess weight daily, watch
for CHF (rales/crackles, jugular vein distension, weight gain, and edema).
Abrupt withdrawal of drug may exacerbate angina symptoms or precipitate
myocardial infarction in patients with coronary artery disease.","• Hypertension: Oral, adult: Initially 100 mg (50 mg for elderly) twice daily,
dose to be increased at intervals of 14 days; usual dose 200 mg twice daily,
increased if necessary up to 800 mg daily in 2 divided doses, higher doses
to be given in 3–4 divided doses; maximum 2.4 g per day. To be taken with
food
• Hypertension/ hypertensive emergencies: Intravenous injection: adult: 50
mg, administer over at least 1 minute, then 50 mg after 5 minutes if required;
maximum 200 mg per course.
• Hypertension/ hypertensive emergencies: Intravenous infusion: adult:
Initially 2 mg/minute until a satisfactory response is achieved, then
discontinue; usual dose 50–200 mg
• Hypertension following myocardial infarction: Intravenous Infusion, adult:
15 mg/hour, maximum dose 120 mg/hour, dose to be increased gradually.
• Hypertension of pregnancy: Intravenous infusion, adult: Initially 20 mg/
hour, then increased if necessary to 40 mg/hour after 30 minutes, then
increased if necessary to 80 mg/hour after 30 minutes, then increased
if necessary to 160 mg/hour after 30 minutes, adjusted according to
response. Maximum 160 mg/hour.
• Hypertension: Oral, child: 4 mg/kg/day in 2 divided doses. Maximum dose
up to 40 mg/kg/day.
• Hypertensive emergencies: Child, intravenous: 0.2-1.0 mg/kg/dose every 10
min as required. Maximum dose: 20 mg/dose
• Hypertensive emergencies: Child, infusion: 0.4-1.0 mg/kg/hr. Maximum
dose 3mg/kg/hr.","Difficulty in micturition, epigastric pain, liver damage,
nausea, postural hypotension, vomiting, weakness, severe hepatocellular
injury (with short or long term use)","Interferes with laboratory tests for
catecholamine. Concurrent use of digitalis increases the risk of bradycardia
Patient’s information: For oral formulation, take medicine after food. Patient
should remain supine up to 3 hrs. after intravenous administration."
NEBIVOLOL,"Tablets: 2.5 mg, 5 mg","Essential hypertension, hypertension in patient with renal
impairment, adjunct in stable mild to moderate heart failure","Avoid in acute or decompensated heart failure requiring intravenous
inotropes, decompensated heart failure, severe hepatic impairment (Child-
Pugh class C). Pregnancy (C). Breast feeding: avoid. Renal impairment: avoid
in heart failure if serum creatinine greater than 250 micromole/liter. Avoid in history of asthma or bronchospasm
(if no alternative, then use with extreme caution and under specialist
supervision), uncontrolled heart failure, prinzemetal angina, bradycardia
(heart rate <50 bpm), hypotension, sick sinus syndrome, second and third
degree atrioventricular block, cardiogenic shock, metabolic acidosis, severe
peripheral arterial disease, pheochromocytoma (unless used with an alpha
blocker). Use caution in patients with first –degree atrioventricular block,
portal hypertension, renal impairment (reduce dose), diabetes mellitus (small
decrease in glucose tolerance, which can mask symptoms of hypoglycemia),
history of hypersensitivity and myasthenia gravis, obstructive airway
disease, portal hypertension, psoriasis. Pregnancy- avoid (IUGR, neonatal
hypoglycemia and bradycardia). Breast feeding: avoid. Monitor lung function
in inadequate cardiac function and bronchospasm disease. Symptoms of
hypoglycemia and thyrotoxicosis may get masked. Assess weight daily, watch
for CHF (rales/crackles, jugular vein distension, weight gain, and edema).
Abrupt withdrawal of drug may exacerbate angina symptoms or precipitate
myocardial infarction in patients with coronary artery disease.","• Essential hypertension: Oral, adult: 5 mg daily; elderly: Initially 2.5 mg daily,
then increased if necessary to 5 mg daily
• Hypertension in patient with renal impairment: Oral, adult: Initially 2.5 mg
once daily, then increased if necessary to 5 mg once daily.
• Adjunct in stable mild to moderate heart failure: Oral, elderly (≥ 70 years):
Initially 1.25 mg once daily for 1–2 weeks, then increased if tolerated to 2.5
mg once daily for 1–2 weeks, then increased if tolerated to 5 mg once daily
for 1–2 weeks, then increased if tolerated to 10 mg once daily.","Bradycardia, gastrointestinal disturbances including
nausea, vomiting, diarrhea, constipation, abdominal cramp, fatigue, cold
hands and feet, hypertriglyceridemia.",
AMLODIPINE,"Tablet: 2.5 mg, 5 mg, 10 mg","Hypertension, angina pectoris","Cardiogenic shock, unstable angina,
significant aortic stenosis. In hepatic impairment: dose reduction. Try to
avoid large amount of alcohol. Pregnancy and breastfeeding: avoid.","• Hypertension or angina: Oral, adult: initially 5 mg once daily; maximum
dose 10 mg once daily.
• Oral, child: 0.1-0.6 mg/kg/day in 1-2 divided doses. Maximum dose: 20 mg/
day","Abdominal pain, nausea, flushing, edema (ankle edema),
headache, dizziness, sleep disturbances, fatigue, alopecia, arthralgia,
asthenia, back pain, dry mouth, dyspnea, impotence, gynecomastia, myalgia,
muscle cramp, skin discoloration.",
FELODIPINE,"Tablet: 2.5 mg, 10 mg","Angina, hypertension","Avoid in Cardiac outflow obstruction, aortic
stenosis uncontrolled heart failure, unstable angina, within 1 month of
myocardial infarction. Predisposition to tachycardia, severe left ventricular
dysfunction, withdraw if cardiogenic shock develops, if ischemic pain occurs
shortly after initiating treatment. Pregnancy- avoid. Breast feeding- safe. In
hepatic impairment, reduce dose.","• Angina: Oral, adult: 5 mg/day, maximum dose 10 mg/day. Oral, elderly: 2.5
mg/day, maximum dose 10 mg/day.
• Hypertension: initially 5 mg (elderly 2.5 mg) daily in the morning; usual
maintenance dose 5-10 mg once daily.","flushing, headache, peripheral edema.",
NIFEDIPINE,"Capsule: 5 mg, 10 mg; Tablet: 30 mg","prophylaxis of angina, hypertension, Raynaud’s phenomenon,
pulmonary hypertension.","Avoid in congestive heart failure or aortic
stenosis, especially in those receiving concomitant beta blocking agents. In
patients with angina, the drug may cause increased angina. Pregnancy (D)","• Hypertension and angina prophylaxis: Oral, adult: 20 mg twice daily. Usual
maintenance 10-40 mg twice daily.
• Raynaud’s phenomenon: Oral, adult: initially 5 mg 3 times daily with or after
food; usual maintenance 5-20 mg 3 times daily.
• Pulmonary hypertension: Oral, adult: 120 to 240 mg once daily dose.
• Hypertension: Child, sublingual: 0.25-0.5 mg/kg/dose may be repeated 6
hourly. Maximum dose 10 mg/dose.
• Hypertension: Child, sustained release tablet: 0.25-3 mg/kg/day in 1-2
divided dose. Maximum dose 120 mg/day
To be taken with or after food.","dizziness, giddiness, flushing, light headedness, peripheral
edema and palpitation.",
CLONIDINE,"Tablet: 25 mcg, 100 mcg.","Hypertension, prevention of recurrent migraine, prevention
of vascular headache, treatment for acute withdrawal in opioid dependent
patients.","Avoid in severe bradyarrhythmia secondary
to second- or third-degree AV block or sick sinus syndrome. Use caution in
cerebrovascular disease, constipation, heart failure, history of depression,
mild to moderate bradyarrhythmia, polyneuropathy, Raynaud’s syndrome
or other occlusive peripheral vascular disease. In hypertension, must be
withdrawn gradually to avoid severe rebound hypertension. Pregnancy: use
caution, may lower fetal heart rate. Breast feeding: avoid. Renal impairment:
Use with caution in severe impairment, reduce initial dose and increase
gradually.","• Hypertension: Oral, adult: Initially 50–100 mcg 3 times a day, increase
initial dose every second or third day, usual maximum dose 1.2 mg daily
• Prevention of recurrent migraine/Prevention of vascular headache: Oral,
adult: Initially 50 micrograms twice daily for 2 weeks, then increased if
necessary to 75 micrograms twice daily
• Treatment for acute withdrawal in opioid dependent patients: Oral, adult:
0.1-0.3 mg every 4-6 hours; increase by 0.1 mg/day; 0.15-0.75 mg/day if
required; do not exceed 2.4 mg/day","Constipation, depression, dizziness, drowsiness, dry mouth,
headache, malaise, nausea, postural hypotension, salivary gland pain,
sexual dysfunction, sleep disturbances, vomiting. Uncommon: bradycardia,
delusion, hallucination, paresthesia, pruritus, rash, Raynaud’s syndrome,
urticarial","concomitant use of alcohol may enhance effects
of alcohol
Patient’s information: Drowsiness may affect performance of skilled tasks
(e.g. driving)"
HYDRALAZINE HYDROCHLORIDE,"Powder for injection: 20 mg in ampoule; Tablet:
25 mg, 50 mg","Moderate and severe hypertension (adjunct), hypertensive
emergencies in pregnant (not a first line agent), hypertension with renal
complication and children","Avoid in severe tachycardia, high output
heart failure, myocardial insufficiency due to mechanical obstruction,
corpulmonale, dissecting aortic aneurysm, porphyria, idiopathic systemic
lupus erythematosus. Use caution in hepatic impairment, renal impairment,
coronary artery disease (may provoke angina, avoid after myocardial
infraction), pregnancy, elderly, cerebrovascular disease. Complete blood
count, LE cell preparation, antinuclear antibody should be performed
before and periodically during prolonged hydralazine therapy. Intravenous
hydralazine is not advisable in older patients, hypertensive patient with
coronary artery disease or cardiovascular risk factors. Monitor blood
glucose regularly in diabetics.","• Mild or moderate hypertension (as adjunct): Oral, adult: 25 mg twice daily,
increased to a maximum of 50 mg twice daily.
• Hypertensive emergencies (including pregnancy/ hypertension with renal
complications): intravenous infusion, adult: initially 200-300 mcg/minute,
maintenance usually 50-150 mcg/minute. Slow intravenous injection, adult:
5-10 mg, to be diluted with 10 ml of 0.9% saline, dose may be repeated
after 20-30 min.
• Hypertension: Oral, child: 0.75-1.0 mg/kg/day in 2-4 divided doses.
Maximum dose: 25 mg/dose. May increase to infants: 5mg/kg/day-,
Children: 7.5 mg/kg/day or 200mg/day
• Hypertension: Child, intravenous or intramuscular: Hypertensive crisis: 0.1-
0.2 mg/kg/dose every 4-6 hours. Maximum dose: 20 mg/dose. Usual IV/IM
dose: 1.7-3.5 mg/kg/day","Tachycardia, palpitation, hypotension, nausea, vomiting,
systemic lupus erythematosus like syndrome, weight gain and headache,
muscle weakness, cramps, dizziness. Patients who are slow acetylator of
hydralazine may have high risk of developing SLE.","With diuretic or other antihypertensives, the
hypotensive effect increases.
Patient’s information: Take drug early in day to avoid nocturia. Rise slowly
from sitting or lying position."
METHYLDOPA,Tablet: 250 mg,"Hypertension, hypertension in pregnancy","Avoid in acute porphyria, depression,
pheochromocytoma. Use cautiously in patients with history of liver disease and
renal impairment, Sino atrial dysfunction; May precipitate severe bradycardia
and sinus arrest. Screening for hepatotoxicity (e.g. with determination of
gamma-glutamyl transpeptidase or alanine aminotransferase) at 3 weeks
then at 3 months following initiation of treatment. Coomb’s test may be
positive in up to 30% of patients, but discontinue only if hemolysis develops.
Pregnancy and breast feeding: safe.","Hypertension, Hypertension in pregnancy: Oral, adult:
250 mg, 2-3 times a day. Single dose administration at bedtime minimizes
sedative effect but it is not sufficient for some patients, dose can be gradually
increased up to 3 g daily (maximum).
Protect the medication from light. Oral, elderly: initially 125 mg twice daily,
increase gradually up to maximum dose of 2 gm daily.","Sedation, dryness of mouth, decreased libido, parkinsonian
signs, hyperprolactinemia, gynecomastia, hepatitis and hepatotoxicity,
hemolytic anemia, leucopenia, lupus like syndrome, myocarditis,
retroperitoneal fibrosis, pancreatitis, malabsorbtion, diarrhea, amenorrhea,
Bell’s palsy, bone marrow depression, depression, eosinophilia, drug fever,
nasal congestion, nightmares, sialadenitis, toxic epidermal necrolysis.",
PRAZOSIN,"Tablet: 1 mg, 2.5 mg, 5 mg","Hypertension, benign prostatic hyperplasia.","Avoid in history of micturition syncope and
postural hypotension, congestive heart failure due to mechanical obstruction
(e.g. aortic stenosis). Use caution cataract surgery (risk of intra-operative
floppy iris syndrome), elderly, renal or hepatic impairment. Pregnancy (C),
Breast feeding: use caution.","• Hypertension: Oral, adult: 500 mcg 2-3 times daily for 3-7 days, the initial
dose on retiring to bed at night; increased to 1 mg 2-3 times daily for further
3-7 days then increased if necessary. Maximum dose 20 mg daily in divided
doses
• Benign prostatic hyperplasia: Oral, adult: Initially 500 mcg twice daily for
3–7 days, subsequent doses should be adjusted according to response,
maintenance 2 mg twice daily, initiate with lowest possible dose in elderly
patients.","Postural hypotension, dizziness, headache, palpitation,
nervousness, drowsiness, priapism, blurred vision, depression, dry
mouth, dyspnea, gastrointestinal disturbances, nasal congestion, edema,
palpitations, syncope, urinary frequency, vertigo, weakness.","Concomitant use with diuretics or other
antihypertensive drug may cause an additive hypertensive effect.
Patient’s information: First dose may cause collapse due to hypotension, take
first dose at bedtime; do not to drive/operate machine for 4 hr. after first
dose."
SODIUM NITROPRUSSIDE,Intravenous solution: 10 mg/ml,"Hypertensive crisis, controlled hypotension in anesthesia, acute
or chronic heart failure.","Severe hepatic impairment, compensatory
hypertension, severe vitamin B12 deficiency, Leber optic atrophy. Elderly,
hyponatremia, hypothermia, hypothyroidism, impaired cerebral circulation,
ischemic heart disease. Impaired pulmonary function; hypothyroidism;
renal impairment, ischemic heart disease, impaired cerebral circulation;
hyponatremia; raised intracranial pressure; Monitor blood pressure and
blood cyanide concentration; monitor blood. Thiocyanate concentration
if given for more than 3 days; avoid sudden withdrawal (reduce infusion
over 15–30 minutes to avoid rebound effects); Pregnancy: Avoid prolonged
use, potential for accumulation of cyanide in fetus. Breast feeding: safety
information not available. Caution advised due to thiocyanate metabolite.","• Hypertensive crisis: Intravenous infusion, adult: initially 0.5–1.5 mcg/
kg/minute, increased gradually to 0.5–6 mcg/kg/minute; (lower doses in
patients already being treated with antihypertensives); maximum, 8 mcg/
kg/minute. Stop infusion, if response is unsatisfactory after 10 minutes at
the maximum dose.
• Heart failure: 10- 15 mcg /minute, increased every 5-10 minutes as
necessary, usual range10-200 mcg/minute.","severe hypotension; associated with over-rapid. Reduction
in blood pressure include headache, dizziness; retrosternal discomfort,
nausea, retching, abdominal pain; perspiration; palpitations, anxiety,
perspiration; rarely reduced platelet count, and acute transient phlebitis.",
TAMSULOSIN,Capsule: 400 mg.,Benign prostatic hyperplasia,"Avoid in micturition syncope, postural
hypotension, severe liver impairment. Use caution if eGFR <10 ml/min/1.73m2.
Dosage schedule: Oral, adult: 400 mcg daily as once daily.","Oral, adult: 400 mcg daily as once daily.","Postural hypotension, dizziness, headache, palpitation,
drowsiness, priapism, pruritus, angioedema, asthenia, blurred vision,
rash, rhinitis, tachycardia, depression, intraoperative floppy iris syndrome,
gastrointestinal disturbances.
Patient’s information: Do not drive, use machinery, or do any activity that
requires alertness until you are sure you can perform such activities safely.
Not to crush, break, chew on oral intake.",
TERAZOSIN,"Tablet: 1 mg, 2 mg, 5 mg.","Benign prostatic hyperplasia (BPH), mild to moderate
hypertension","Avoid in history of micturition syncope and
postural hypotension, congestive heart failure due to mechanical obstruction
(e.g. aortic stenosis). Use caution cataract surgery (risk of intra-operative
floppy iris syndrome), elderly, renal or hepatic impairment. Pregnancy (C),
Breast feeding: use caution.","• Hypertension (mild to moderate): Oral, adult: Initially 1 mg once daily at
bedtime, dose doubled after 7 days if necessary, usual maintenance dose
2-10 mg according to response.
• BPH: Oral, adult: Initially 1 mg orally once daily at a bedtime. If necessary
dose may be doubled at intervals of 1-2 weeks according to response,
maintenance 5–10 mg daily; maximum 10 mg per day.","Postural hypotension and syncope (especially on the start
of therapy), dizziness, drowsiness, dry mouth, chest pain, pedal edema,
palpitation, headache, priapism, thrombocytopenia, decreased libido,
erectile disorders, weight gain, dyspnea, Angioedema, pain in extremities,
blurred vision","With Metoprolol causes additive hypotensive
effect"
PHENYLEPHRINE,Solution: 10 mg/ml,"Acute hypotension, Priapism","Avoid in hypertension, severe hyperthyroidism.
Hypertensive response of Phenylephrine has a longer duration of action than
noradrenaline (norepinephrine) and an excessive vasopressor response may
cause a prolonged rise in blood pressure. Pregnancy: avoid","• Acute hypotension: subcutaneous injection/ intramuscular injection, adult:
Initially 2–5 mg, followed by 1–10 mg, after at least 15 minutes, if required.
Slow intravenous injection, adult: 100–500 mcg, repeated as necessary
after at least 15 minutes; 1 mg/ ml solution to be used. Intravenous infusion,
adult: Initially up to 180 mcg /minute, reduced to 30–60 mcg/min, adjusted
according to response. Intravenous infusion give intermittently in Glucose
5% or Sodium chloride 0.9%. Dilute 10 mg in 500 mL infusion fluid.
• Priapism: Intracavernosal injection, adult: 100–200 mcg every 5–10 minutes;
maximum 1 mg per course. For intracavernosal injection, if suitable strength
of phenylephrine injection is not available, it may be specially prepared by
diluting 0.1 mL of the phenylephrine 1% (10 mg/mL) injection to 5 mL with
sodium chloride 0.9%.","Arrhythmias, hypertension, palpitation, tachycardia, angle-
closure glaucoma, anorexia, anxiety, bradycardia (also reflex bradycardia),
confusion, dyspnea, headache, hypoxia, insomnia, nausea, peripheral
ischemia, psychosis, tremor, urinary retention, vomiting, weakness",
DOBUTAMINE,Injection solution: 12.5 mg/ml in 20 ml vial.,"Inotropic support in infarction, cardiac surgery, septic shock,
cardiogenic shock and during positive end expiratory pressure ventilation.","Avoid
in
hypersensitivity,
pheochromocytoma. Use caution in severe hypotension, complicating
cardiogenic shock, heart failure.","Intravenous infusion, adult: 2.5-10 mcg/kg/minute,
adjusted according to response, alternatively 0.5-40 mcg/kg/min","Tachycardia, increase in systolic blood pressure, phlebitis.
Extravasation of the drug causes tissue necrosis","Additive (synergistic) effective with
Nitroprusside. Atenolol may negate the effect of dopamine. Do not mix with
sodium bicarbonate, furosemide and other alkaline solutions."
DOPAMINE,"Injection: 40 mg/ml in 5ml, 10ml vial.","Cardiogenic shock including in myocardial infarction and
cardiac surgery.","Avoid in tachyarrhythmia, ventricular
fibrillation, ischemic heart disease; pheochromocytoma, hyperthyroidism.
Correct hypovolemia before, and maintain blood volume during the
treatment; correct hypoxia, hypercapnia, and metabolic acidosis before or
at same time as starting treatment; use low dose in cardiogenic shock due to
myocardial infarction; history of peripheral vascular disease (increased risk
of ischemia of extremities. Pregnancy: use only if potential benefit outweighs
risk. Breast Feeding: May suppress lactation.","Cardiogenic shock: intravenous infusion, adult: initially
2–5 mcg/kg/minute into a large vein (preferably via central venous catheter),
gradually increased by 5-10 mcg/kg/minute according to blood pressure,
cardiac output, and urine output (seriously ill patients, up to 20–50 mcg/
kg/minute)
Prepared immediately before use in accordance with the manufacture’s
instruction. Protect medication from light.","Nausea, vomiting, peripheral vasoconstriction; hypotension
with dizziness, fainting, flushing; tachycardia, ectopic beats, palpitations,
anginal pain; headache, dyspnea; hypertension particularly in over dosage.
Extravasation of the drug causes tissue necrosis.","Propranolol and Metoprolol antagonize the
cardiac effects of dopamine. Ventricular arrhythmias and hypertension may
occur with halothane or cyclopropane anesthesia."
EPINEPHRINE /ADRENALINE,Injection: 1 mg in 1000 ml,"Cardiac arrest, adjunct with local anesthetics, acute anaphylaxis","Shock (other than anaphylactic shock),
second stage labor. Do not use the drug if the color of the injection is cloudy
or brownish. While using this drug monitor blood pressure, heart rate.","Acute anaphylaxis: intramuscular injection, adult: 0.5-1
ml, to be repeated every 10 minutes according to blood pressure and pulse,
until improvement occurs. Intramuscular injection, child (2-5 years): 0.2-0.4
ml; (6-12 years): 0.5 ml. Dosage to be repeated as in adult.
Acute hypotension: continuous intravenous infusion, neonate and child: 100
nanogram/kg/min (up to 1.5 mcg/kg/min) adjusted according to response.
Cardiopulmonary resuscitation: Intravenous injection, adult: 1 mg every 3-5
min as required, 1 in 10000(100 mcg/ml) solution is recommended.","Tachycardia, hypertension, tremor, chest pain, irregular
heartbeats, headache, nausea, vomiting, nervousness, restlessness, and
weakness.","It should be avoided in patients who are on
tricyclic antidepressants as it may be cause arrhythmias, hypertension or
tachycardia.
Patient’s information: Notify doctor if side effects (anaphylaxis) are seen."
MILRINONE,"Injection: 1 mg/ml, 10mg/10ml solution in
ampoules.","Short-term treatment of severe congestive heart failure
unresponsive to conventional maintenance therapy (not immediately after
myocardial infarction), acute heart failure, including low output states
following heart surgery","Avoid in severe hypovolemia. Use caution
in hypokalemia, renal impairment, heart failure associated with hypertrophic
cardiomyopathy, stenotic or obstructive valvular disease or other outlet
obstruction. Pregnancy: use with caution- use only if potential benefit
outweighs risk. Breast feeding: avoid.","Short-term treatment of severe congestive heart failure
unresponsive to conventional maintenance therapy (not immediately after
myocardial infarction)/ acute heart failure, including low output states
following heart surgery: intravenous injection, adult: Initially 50 mcg/kg,
given over 10 minutes, followed by intravenous infusion 375–750 nanogram/
kg/minute usually given following surgery for up to 12 hours or in congestive
heart failure for 48-72 hours; maximum dose: 1.13 mg/kg per day. Renal
impairment: Reduce dose and monitor response if eGFR < 50 mL/min/1.73 m2","Ectopic beats, headache, hypotension, supraventricular
arrhythmias (more likely in patients with pre-existing arrhythmias),
ventricular tachycardia. Less commonly seen: Chest pain, hypokalemia,
thrombocytopenia, tremor, ventricular fibrillation.",
NOREPINEPHRINE/NORADRENALINE,"Injection: 1 mg/ml. Noradrenaline (base) 4 mg/4
ml concentrate for solution for infusion ampoules.",Acute hypotension,"Hypertension. Use caution in coronary
vascular thrombosis, diabetes mellitus, elderly, following myocardial
infarction, hypercapnia, hyperthyroidism, hypoxia, mesenteric vascular
thrombosis, peripheral vascular thrombosis, variant angina, uncorrected
hypovolemia. Pregnancy: Avoid, may reduce placental perfusion.","Acute hypotension: intravenous, adult: Initially 0.16–0.33
mL/minute, solution containing noradrenaline 40 mcg (base)/ml, adjusted
according to response into large vein (preferably via central venous catheter).
1 mg of noradrenaline base is equivalent to 2 mg of noradrenaline acid
tartrate. Doses expressed as the base. For treatment of acute hypotension
in adults, use a solution containing noradrenaline 40 mcg (base)/ml. For
intravenous infusion, give continuously in Glucose 5% or 0.9% saline and
glucose via a controlled infusion device. For administration via syringe
pump, dilute 2 mg (2 mL of solution) noradrenaline base with 48 mL infusion
fluid. For administration via drip counter dilute 20 mg (20 mL of solution)
noradrenaline base with 480 mL infusion fluid; preferably through a central
venous catheter; incompatible with alkalis.","Angle-closure glaucoma, anorexia, anxiety, arrhythmias,
bradycardia, confusion, dyspnea, headache, hypertension, hypoxia,
insomnia, nausea, palpitation, peripheral ischemia, psychosis, tachycardia,
tremor, urinary retention, vomiting, weakness. Avoid extravasation, may
cause pain and subcutaneous tissue ischemia at the site.",incompatible with alkalis.
BOSENTAN,"Tablet: 62.5 mg, 125 mg","Pulmonary arterial hypertension, systemic sclerosis with
ongoing digital ulcer disease (to reduce number of new digital ulcers)","Avoid in acute porphyria, systemic systolic
blood pressure is <85 mmHg. Pregnancy (X) Breast feeding: avoid. Hepatic
impairment: avoid in moderate to severe impairment. Effective contraception
required during administration (hormonal contraception not considered
effective). Monthly pregnancy tests advised. Monitor: Hemoglobin before
and during treatment (monthly for first 4 months then 3-monthly); Liver
function before treatment, at monthly intervals during treatment and 2
weeks after dose increase (reduce dose or suspend treatment if liver enzymes
raised significantly)—discontinue if symptoms of liver impairment.","• Pulmonary arterial hypertension: Oral, adult: Initially 62.5 mg twice daily
for 4 weeks, then increased to 125 mg twice daily; maximum 500 mg per day
in 2 divided doses.
• Systemic sclerosis with ongoing digital ulcer disease (to reduce number of
new digital ulcers): Oral, adult: Initially 62.5 mg twice daily for 4 weeks, then
increased to 125 mg twice daily
Avoid abrupt withdrawal.","Anemia, diarrhea, flushing, gastro-esophageal reflux,
headache, hypotension, edema, palpitation, syncope, liver cirrhosis, liver
failure, leucopenia, neutropenia, thrombocytopenia.",
SILDENAFIL,"Tablet: 25 mg, 50 mg, 100 mg","Pulmonary arterial hypertension (PAH), erectile dysfunction","Avoid in hypotension, myocardial
infarction, unstable angina, not for use in children with PAH. Use caution in
patients with anatomic deformation of penis, retinitis pigmentosa, ischemic
heart disease.","Erectile dysfunction: Oral, adult: 50 mg 1 hr. before sexual activity, maximum
dose 100 mg or minimum dose 25 mg and maximum of 1 dose per day.
PAH: Oral, adult: 25 mg three times daily.","headache, flushing, epistaxis, dyspepsia, insomnia,
erythema, diarrhea, migraine, myalgia, nasal congestion, visual disturbance,
back pain.",
ATORVASTATIN,Tablet: 10 mg,"Primary hypercholesterolemia, homozygous or heterozygous
familial hypercholesterolemia or mixed hyperlipidemia in patients who have
not responded adequately to diet and other appropriate measures.","Avoid in pregnancy, breastfeeding, active
liver disease (or in patients with persistently abnormal lover function tests).
Use caution in patients with liver disease, elderly or with a high alcohol
intake. Non serious and reversible cognitive side effects may occur. Liver
function tests should be carried out before and within 1-3 months of starting
treatment and thereafter at intervals of 6 months for 1 year, unless indicated
sooner by signs or symptoms suggestive of hepatotoxicity.","• Primary hyperlipidemia and combined hyperlipidemia: Oral, adult: 10 mg
once daily; if necessary may be increased at intervals of at least 4 weeks
to maximum 80 mg once daily. Oral, child (10-13 years usually): 10 mg once
daily.
• Familial hypercholesterolemia: Oral, adult: initially 10 mg daily, increased
at intervals of at least 4 weeks to 40 mg once daily; if necessary, further
increased to maximum 80 mg once daily. Oral, child (10-13 years): up to 20
mg once daily.","reversible myositis, headache, angina, chest pain, arthralgia,
anorexia, weight gain, epistaxis, back pain, nasopharyngitis, hyperglycemia.","With clarithromycin increases plasma
concentration of atorvastatin. Reduced dose required (max. 10 mg daily) with
concomitant cyclosporine/ tipranavir combined with ritonavir. Maximum
dose of 40 mg once daily when combined with anion-exchange resin for
heterozygous familial hypercholesterolemia. Use with caution in patient with
high alcohol intake."
CHOLESTYRAMINE RESINS,Powder (sachet): 4 gm,"Adjunct to dietary therapy to decrease elevated serum
cholesterol and LDL concentrations, cholestasis induced pruritus.",Avoid in severe hypertriglyceridemia.,"• Lipid reduction (after initial introduction over 3-4 week): Oral, adult: 12-24 g
daily in water in single or up to 4 divided doses, up to 36 g daily if necessary
• Cholestasis induced pruritus: Oral, adult: 4-8 g daily in water.","Bloating, dyspepsia, constipation, abdominal pain and
distention, anorexia, biliary colic, and skin rash.","Long term high-dose cholestyramine therapy
may impair the absorption of fat-soluble vitamins. Concomitant use causes
reduced absorption of thyroid hormones, warfarin.
Patient’s information: Adverse effects can be substantially reduced if the
drug is completely suspended in liquid several hours before ingestion (e.g.
evening doses can be mixed in morning and refrigerated similarly morning in
previous evening)"
EZETIMIBE,Tablet: 10 mg.,"Adjunct to dietary measures and statin treatment in primary
hypercholesterolemia, adjunct to dietary measures and statin in homozygous
familial hypercholesterolemia, Primary hypercholesterolemia (if statin
inappropriate or not tolerated), Adjunct to dietary measures in homozygous
sitosterolemia","Avoid in moderate to severe hepatic
impairment, myopathy, elevated hepatic transaminases, renal impairment
(CrCl less than or equal to 30 ml/min/1.73 m2). Pregnancy (C) Breast feeding:
avoid.","Oral, adult: 10 mg daily","Fatigue, gastro-intestinal disturbances, headache, myalgia.
Rare: anaphylaxis, angioedema, arthralgia, hepatitis, hypersensitivity
reactions, rash. Very rare: cholecystitis, cholelithiasis, myopathy, pancreatitis,
raised creatine kinase, rhabdomyolysis, and thrombocytopenia","An increased risk of rhabdomyolysis if Ezetimibe
is used in combination with a statin. Avoid use with cyclosporine."
FENOFIBRATE,Capsule: 160 mg,Severe hypertriglyceridemia,"Avoid in gall bladder disease,
hypoalbuminemia, nephrotic syndrome, during pregnancy, breast feeding,
severe hepatic impairment. Use caution in mild to moderate renal and hepatic
impairment. Monitor serum liver transaminases enzymes every 3 month for a
year then periodically during therapy",Initially 160 mg once daily dose.,"Gastrointestinal disturbances, rash, urticaria, fatigue,
headache, impotence.","Avoid use with ketoprofen, other fibrates,
photosensitivity seen.
Patient’s information: Restrict fat diet during the therapy."
GEMFIBROZIL,Capsule: 300 mg,"Adjunct to dietary therapy in hyperlipidemias of types II a, II b,
III, IV and V.","Avoid in preexisting gallbladder disease,
hepatic dysfunction, history of hypersensitivity to the drug. Risk for
myopathy/ rhabdomyolysis increases with renal impairment. Assess the liver
function test, CBC and electrolytes every 3-6 months and then yearly during
therapy. Safety and efficacy in children younger than 18 years of age have
not been established. Pregnancy (C). Breast feeding: Avoid","Oral, adult: 1.2 g daily usually in 2 divided doses; range
0.9-1.2 g daily.","abdominal and epigastric pain, diarrhea, nausea, anorexia,
headache, sexual dysfunction, myopathy, myositis, urticaria and pruritus.","May potentiate the anticoagulant effects
of oral anticoagulants, may increase the effects of sulfonylurea and oral
hypoglycemia agents."
NICOTINIC ACID (NIACIN),"Tablet: 50 mg, 250 mg","Adjunct to statin in hypertriglyceridemia and or used alone if
statin not tolerated.","Avoid in arterial hemorrhage, active peptic
ulcer, and breast feeding. Use caution in liver disease, gout, diabetes mellitus,
gallbladder disease, renal impairment. Pregnancy (A, C- for doses exceeding
RDA). Breast feeding: use caution.","Oral, adult: Initially 100-200 mg 3 times daily, gradually
increased over 2-4 weeks to l-2 g 3 times daily.","diarrhea, nausea, vomiting, flushing, palpitations, dizziness,
pruritus and rash.","May potentiate the anticoagulant effects of
oral anticoagulants. Increased risk of rhabdomyolysis and other toxicitites
with HMC co-A reductase inhibitors."
SIMVASTATIN,"Tablet: 5 mg, 10 mg, 20 mg, 40 mg","Primary and secondary prevention of atherosclerotic
cardiovascular disease, in high risk individuals (e.g. with diabetes mellitus,
post Myocardial infarction)","Avoid in pregnancy(X), breast-feeding,
active liver disease (or in patients with persistently abnormal liver function
tests). Use caution in elderly (>65 years), hepatic or renal dysfunction, and
uncontrolled hypothyroidism and perioperative periods and other factors
inhibiting statin catabolism due to increased risk of myopathy. Dose should
be reduced if the aforementioned drugs should be used concomitantly. As
soon as myopathy is suspected, blood analysis should be done to document
significant elevation of creatinine phosphokinase (CPK) levels (>3 times the
upper limit of normal) then statin use should be discontinued.","For prevention of cardiovascular events: Oral, adult:
initially 20-40 mg once daily at night (maximum 80 mg once daily at
night- only for those with severe hypercholesterolemia and at high risk of
cardiovascular complications).","Upper respiratory tract infection, myalgia, myopathy
(dose dependent), myositis, rhabdomyolysis, eosinophilia, eczema,
vertigo, abdominal pain, dyspepsia, raised serum transaminases, hepatitis,
jaundice, peripheral neuropathy, paresthesia, anemia, alopecia, and rashes,
hypersensitivity reactions (angioedema and anaphylaxis), cognitive side
effects (non serious and reversible), hyperglycemia (HbA1c and fasting
glucose level increase), immune mediated necrotizing myopathy (rare)","With gemfibrozil, cyclosporine, digoxin,
warfarin, verapamil, diltiazem, macrolide antibiotics (erythromycin,
clarithromycin), azole antifungals, niacin, HIV protease inhibitors, and
amiodarone. These drug reduce the catabolism of statins and cause
myopathy and rhabdomyolysis"
ROSUVASTATIN,Tablet: 5 mg,"Primary hypercholesterolemia (type IIa including heterozygous
familial hypercholesterolemia), mixed dyslipidemia (type IIb), or homozygous
familial hypercholesterolemia in patients who have not responded adequately
to diet and other appropriate measures with or without high cardiovascular
risk, Prevention of cardiovascular events in patients at high risk of a first
cardiovascular event and with risk factors for myopathy or rhabdomyolysis","Avoid in pregnancy, breast feeding,
severe renal impairment (eGFR less than 30 ml/ minute/1.73 m2), hepatic100
NNF 2018
impairment. Use caution in mild to moderate renal impairment. In patients
with high cardiovascular risk. Breast feeding: avoid.","• Primary hypercholesterolemia (type IIa including heterozygous familial
hypercholesterolemia), mixed dyslipidemia (type IIb), or homozygous familial
hypercholesterolemia in patients who have not responded adequately to
diet and other appropriate measures / Prevention of cardiovascular events
in patients at high risk of a first cardiovascular event and with risk factors
for myopathy or rhabdomyolysis: Oral, adult: Initially 5 mg once daily, then
increased if necessary up to 20 mg once daily, dose to be increased at
intervals of at least 4 weeks.
• Severe primary hypercholesterolemia in patients with high cardiovascular
risk (under expert supervision): Oral, adult: Initially 5–10 mg once daily,
increased if necessary to 20 mg once daily, then increased if necessary to
40 mg once daily, dose to be increased at intervals of at least 4 weeks
• Dose adjustments with concomitant fibrate: Initially 5 mg once daily
increased if necessary to max. 20 mg daily.
• Renal impairment (eGFR 30–60 ml/minute/1.73 m2): Initially 5 mg once daily
(do not exceed 20 mg daily)","Flulike symptoms, constipation, urinary tract infection,
proteinuria. Gynecomastia, hematuria, peripheral neuropathy, arthralgia.",
FERROUS FUMARATE,"Tablet: 200 mg containing 65 mg of elemental
iron",Iron-deficiency anemia,"Hemochromatosis,
hemosiderosis,
hemolytic anemia (unless iron deficiency state is also present), any form of
anaemia not caused by iron deficiency; patients receiving repeated blood
transfusions; parenteral iron therapy. The hemoglobin concentration should
rise by about 100-200 mg/100 mL (1-2 g/L) per day or 2 g/100 mL (20 g/L)
over 3–4 weeks. Although iron preparations are best absorbed on an empty
stomach, they may be taken after food to reduce gastrointestinal adverse
effects; they may discolour stools","• Iron deficiency anemia (prophylactic): Oral, > 12 years: 210 mg elemental
iron 1–2 times a day.
• Iron deficiency anemia (therapeutic): Oral, 12 years: 210 mg 2–3 times a day","Diarrhea and constipation, nausea, epigastric pain and
heart burn. Liquid preparations containing iron salts should be well diluted
with water. If possible, swallowed through a drinking straw to prevent
discoloration of teeth.","Concurrent administration with antacids and
tetracyclines with oral iron preparation will inhibit absorption of tetracyclines
and iron. Citric acid and ascorbic acid increases the absorption of iron.
Patient information: Take missed dose as soon as remembered within 12 hr.
Do not double the dose. Advise patient that stool may become dark green or
black and this is harmless."
FERROUS FUMARATE with FOLIC ACID,"Tablet: Ferrous fumarate: 322 mg and Folic acid
350 mcg; Capsule: Ferrous fumarate 305 mg and Folic acid 350 mcg.",Iron deficiency anemia,,"Oral, adult: 1 tablet/capsule daily, to be taken before food",Tablets: 300 mg.,
FERROUS GLUCONATE,Tablets: 300 mg.,"Prophylaxis and treatment of iron deficiency anemia,","Hemochromatosis,
hemosiderosis,
hemolytic anemia (unless iron deficiency state is also present), any form of
anaemia not caused by iron deficiency; patients receiving repeated blood
transfusions; parenteral iron therapy. The hemoglobin concentration should
rise by about 100-200 mg/100 mL (1-2 g/L) per day or 2 g/100 mL (20 g/L)
over 3–4 weeks. Although iron preparations are best absorbed on an empty
stomach, they may be taken after food to reduce gastrointestinal adverse
effects; they may discolour stools.","• Prophylaxis of iron-deficiency anemia: oral, child (6–11 years): 300–900 mg
daily, child (12–17 years): 600 mg daily, dose to be taken before food, Adult:
600 mg daily, dose to be taken before food.
• Treatment of iron-deficiency anemia: oral, child (6–11 years): 300–900 mg
daily, child (12–17 years): 1.2–1.8 g daily in divided doses, adult: 1.2–1.8 g
daily in divided doses, dose to be taken before food","Diarrhea and constipation, nausea, epigastric pain and
heart burn. Liquid preparations containing iron salts should be well diluted
with water. If possible, swallowed through a drinking straw to prevent
discoloration of teeth.","Concurrent administration with antacids and
tetracyclines with oral iron preparation will inhibit absorption of tetracyclines
and iron. Citric acid and ascorbic acid increases the absorption of iron.
Patient information: Take missed dose as soon as remembered within 12 hr.
Do not double the dose. Advise patient that stool may become dark green or
black and this is harmless."
FERROUS SULPHATE,"Tablet: 300 mg contains 60 mg of elemental
iron, 200 mg contains 40 mg of elemental iron.",Iron deficiency anemia,"Hemochromatosis,
hemosiderosis,
hemolytic anemia (unless iron deficiency state is also present), any form of
anaemia not caused by iron deficiency; patients receiving repeated blood
transfusions; parenteral iron therapy. The hemoglobin concentration should
rise by about 100-200 mg/100 mL (1-2 g/L) per day or 2 g/100 mL (20 g/L)
over 3–4 weeks. Although iron preparations are best absorbed on an empty
stomach, they may be taken after food to reduce gastrointestinal adverse
effects; they may discolour stools.","• Prophylaxis: 200 mg dried ferrous sulfate daily after food.
• Treatment: 400-600 mg daily in divided doses after food.","Diarrhea, constipation, nausea, epigastric pain (dose
related)","Concurrent administration with antacids and
tetracyclines with oral iron preparation will inhibit absorption of tetracyclines
and iron. Citric acid and ascorbic acid increases the absorption of iron.
Patient information: Take missed dose as soon as remembered within 12 hr.
Do not double the dose. Advise patient that stool may become dark green or
black and this is harmless."
FERROUS SULFATE WITH ASCORBIC ACID,"Tablet: Ferrous sulphate 325 mg and Sodium
ascorbate 500 mg",Iron deficiency anemia,,"Oral, adult: 1 tablet daily, dose to be taken before food",,
FERROUS SULPHATE with FOLIC ACID,"Tablet: Elemental iron 60 mg and Folic acid 400
mcg",Prevention of iron and folic acid deficiencies in pregnancy,"Should never be given without vitamin B12
in undiagnosed megaloblastic anaemia or other vitamin B12 deficiency states
because of the risk of precipitating subacute combined degeneration of the
spinal cord; folate-dependent malignant disease. Also see under ferrous
fumarate.","• Severe anaemia: Oral, child <2 years, elemental iron, 25 mg + folic acid 100–
400 mcg daily for 3 months. Child 2–12 years, elemental iron 60 mg + folic
acid, 400 mcg daily for 3 months. Adult, elemental iron, 120 mg + folic acid
400 mcg daily for 3 months.
• Prevention of iron and folate deficiencies in pregnancy: Oral, adult: elemental
iron, 100 mg + folic acid, 350–400 mcg daily throughout pregnancy.","Diarrhea, constipation, nausea, epigastric pain (dose
related)","Concurrent administration with antacids and
tetracyclines with oral iron preparation will inhibit absorption of tetracyclines
and iron. Citric acid and ascorbic acid increases the absorption of iron.
Patient information: Take missed dose as soon as remembered within 12 hr.
Do not double the dose. Advise patient that stool may become dark green or
black and this is harmless."
FOLIC ACID,Tablet: 1 mg and 5 mg,"Folate deficiency megaloblastic anemia; prevention of neural
tube defect in pregnancy.","Should never be given without vitamin B12
in undiagnosed megaloblastic anaemia or other vitamin B12 deficiency states
because risk of precipitating subacute combined degeneration of spinal cord;
folate dependent malignant disease. Women receiving antiepileptic therapy
need counselling before starting folic acid. Monitor plasma folic acid levels,
hemoglobin, hematocrit and reticulocyte count before and after therapy.","• Treatment of folate deficiency megaloblastic anemia: Oral, adult: 5 mg
daily for 4 months (in pregnancy continued to term ); ≤15 mg daily may be
necessary in malabsorption states.
• Prevention of first occurrence of neural tube defect: Oral, adult: 400-500
mg daily before conception and during the first twelve weeks of pregnancy.
• Prevention of recurrence of neural tube defects: Oral, adult: 5 mg daily
(reduced to 4 mg daily) from at least 4 weeks before conception until
twelfth weeks of pregnancy.","Bronchospasm, erythema, malaise, pruritis, rash, slight
flushing","Pyrimethamine, methotrexate, trimethoprim
and triamterene prevent the activation of folic acid. Absorption of folic
acid is decreased by sulphonamide, antacids and cholestyramine. Folic
acid requirements are increased by estrogens, phenytoin, phenobarbital,
primidone, carbamazepine or corticosteroids. Folic acid may cause decrease
in serum concentrations of other vitamin B complex when given in high
continuous doses
Patient information: Urine may turn intensely yellow which is normal with
therapy. Encourage females to take folic acid in early pregnancy as it prevents
neural tube defects of children."
WARFARIN,"Tablet: 1 mg, 2 mg, 5 mg","Prevention of progression and recurrence of deep venous
thrombosis or pulmonary embolism following a initial course of heparin.
It is effective in prevention of thromboembolism in patients undergoing
gynecological and surgical procedure, acute MI, prosthetic heart valves or
chronic atrial fibrillation.","Patients with GI ulcers, severe
hypertension, bacterial endocarditis, pregnancy. Pregnancy category X.
Contraindicated in women who are or may become pregnant. Hepatic and
renal impairment, recent surgery, breast feeding","Initial dose 10 mg for 2 days, subsequent doses 3-9 mg
daily in accordance with the prothrombin activity of blood",,"Food in GI tract can decrease rate of
absorbtion. Barbiturates, rifampicin, phenytoin, chronic alcohol ingestion,
ingestion of large amount of Vit K rich food or supplements may cause
decreased effects of warfarin. Decreased metabolism and/or displacement
from protein binding site may be caused by phenylbutazone, metronidazole,
allopurinol, cimetidine, amiodarone, thus enhancing risk of hemorrhage
Patient information: Avoid OTC preparation that may cause serious product
interaction unless directed by prescriber. Patients should report any sign of
bleeding: gum, under skin, urine, and stool and avoid hazardous activities
(e.g. hockey, football)"
ACENOCOUMAROL,"Tablet: 1 mg, 2 mg, 3 mg and 4 mg.","Prevention of progression and recurrence of deep venous
thrombosis or pulmonary embolism following a initial course of heparin.
It is effective in prevention of thromboembolism in patients undergoing
gynecological and surgical procedure, acute MI, prosthetic heart valves or
chronic atrial fibrillation.","Patients with GI ulcers, severe
hypertension, bacterial endocarditis, pregnancy. Pregnancy category X.
Contraindicated in women who are or may become pregnant. Hepatic and
renal impairment, recent surgery, breast feeding","4-12 mg on first day, 4-8 mg on second day, maintenance
dose usually 1-8 mg daily.",,
APIXABAN,"Tablet: 2.5 mg, 5 mg","Stroke prophylaxis with atrial fibrillation, postoperative
prophylaxis of deep vein thrombosis/pulmonary embolism, deep vein
thrombosis or pulmonary embolism.","Active bleeding, malignant neoplasms,
oesophageal varices, recent brain surgery, recent gastro-intestinal ulcer,
recent intracranial, haemorrhage, recent ophthalmic surgery, recent spine
surgery, significant risk of major bleeding, vascular aneurysm. Anaesthesia
with postoperative indwelling epidural catheter (risk of paralysis), prosthetic
heart valve, risk of bleeding, pregnancy category B, lactation. Patients with
nonvascular atrial fibrillation and or spinal or epidural hematoma.","• Stroke prophylaxis with atrial fibrillation: adult, oral: 5 mg twice a day,
• Postoperative prophylaxis of deep vein thrombosis/pulmonary embolism:
2.5 mg per oral twice a day for 35 days,
• Deep vein thrombosis or pulmonary embolism: adult, oral: 10 mg twice a
day for 7 day, then 5 mg twice a day.","Anaemia, bruising, haemorrhage, nausea","Analgesics and anticoagulants (increases risk
of haemorrhage), antibacterial, antidepressants, antiepileptics (decreases
plasma concentration of rivaroxaban), antifungal and antiviral (increases
plasma concentration of rivaroxaban)."
DABIGATRAN,Capsule: 75 mg and 150 mg,"Stroke prophylaxis with atrial fibrillation, DVT/pulmonary
embolus treatment and or prophylaxis.","Severe renal impairment (CrCl <15 mL/min)
or haemodialysis, hypersensitivity, active pathologic bleeding, impairment of
haemostasis. Increased bleeding risk during labor and delivery, discontinue
1-2 days (CrCl ≥50 mL/min) or 3-5 days (CrCl <50 mL/min) before invasive
or surgical procedure to decrease bleeding risk, monitor Ecarin clotting time
(ECT), if unavailable than monitor aPPT, PT, or TT; aPPT. Also see under
apixaban and fondaparinux.","• Stroke prophylaxis with atrial fibrillation: adult, oral: CrCl >30 mL/min: 150
mg twice a day, CrCl 15-30 mL/min: 75 mg PO twice a day,
• DVT/pulmonary embolus treatment: adult, oral: CrCl >30 mL/min: 150 mg
twice a day,
• DVT/pulmonary embolus treatment prophylaxis: adult, oral: CrCl >30 mL/
min: 110 mg 1-4 hr after surgery and after haemostasis has been achieved
on first day, then 220 mg taken once a day for 28-35 days.","Dyspepsia, gastritis, intracranial hemorrhage,
hypersensitivity including urticaria, rash, pruritic.",
RIVAROXABAN,"Tablets: 10 mg, 15 mg and 20 mg","Prophylaxis of venous thromboembolism (orthopaedic surgery),
deep vein thrombosis, pulmonary embolism, nonvalvular atrial fibrillation.","Hypersensitivity, active bleeding, malignant
neoplasms, oesophageal varices, recent brain surgery, GI ulcer, vascular
aneurysm.Anaesthesia with postoperative indwelling epidural catheter (risk of
paralysis), bronchiectasis, prosthetic heart valve, risk of bleeding, pulmonary
embolism in patients with haemodynamic instability, severe hypertension,
vascular retinopathy. Also see under apixaban and fondaparinux.","• Prophylaxis of venous thromboembolism (orthopaedic surgery): oral, adult:
10 mg once a day for 12 days,
• Deep vein thrombosis or pulmonary embolism: oral, adult: 15 mg twice a
day for 21 days then 20 mg per oral once a day for 6 months.","Abdominal pain, constipation, diarrhoea, dizziness,
dyspepsia haemorrhage, headache, hypotension, nausea, pain in extremities,
pruritus, rash, renal impairment, vomiting","Analgesics and anticoagulants (increases risk
of haemorrhage), antibacterial, antidepressants, antiepileptics (decreases
plasma concentration of rivaroxaban), antifungal and antiviral (increases
plasma concentration of rivaroxaban)."
ASPIRIN,"Tablet: 50 mg, 75 mg and 300 mg.","Prophylaxis of cerebro vascular diseases, and myocardial
infarction, thromboembolic disorder, post-MI, ischemic stroke and angina","Antiplatelet drugs are not used in
the management of haemorrhagic stroke, hypersensitivity (including
asthma, angioedema, urticaria) to
acetylsalicyclic, active
peptic
ulceration,haemophilia and other bleeding disorder. Asthma, uncontrolled
hypertension, pregnancy. Tell the patient to take aspirin after food with full
glass of plenty of water to reduce stomach irritation. Aspirin should not be
given to children and adolescent due to Reye’s syndrome. Watch for signs of
bleeding. Watch for the sign of salicylate poisioning.","• Thromboembolic disorders: Adult: oral 325-650 mg/day.
• Transient ischemic attack: adult oral 50-325 mg/day.
• Evolving MI with ST segment elevation: adult oral 160-325 mg nonenteric,
chewed and swallowed immediately, maintenance 75-162 mg/day MI,
• Stroke prophylaxis: adult oral 50-325 mg/day","Bronchospasm, GI bleeding, thrombocytopenia, seizures,
Reye’ syndrome","Aspirin may increase the effects of oral
hypoglycemic effects.if it is given with anticoagulant; the chance of bleeding
will be increased."
CLOPIDOGREL,Tablet: 75 mg,"Prevention of atherothrombotic events, transient ischaemic
attack or acute ischaemic stroke for patients with aspirin hypersensitivity/
intolerant of aspirin, Prevention of artherothrombotic events in acute
coronary syndrome with or without ST-segment elevation (given with aspirin)","Hypersensitivity, Coagulation disorders,
active pathological bleeding. Risk of increased bleeding form trauma, surgery
or other pathological conditions. Pregnancy: Avoid, hepatic and renal
impairment: use with caution.","• Prevention of atherothrombotic events in percutaneous coronary
intervention (adjunct with aspirin) in patients not already on clopidogrel:
Adult, oral: Loading dose 300 mg, to be taken prior to the procedure, Or
loading dose 600 mg, higher dose may produce a greater and more rapid
inhibition of platelet aggregation
• Transient ischaemic attack for patients with aspirin hypersensitivity/
intolerant of aspirin, acute ischaemic stroke for patients with aspirin
hypersensitivity/ intolerant of aspirin: Adult, oral: 75 mg once daily
• Prevention of atherothrombotic events in peripheral arterial disease or
within 35 days of MI/ within 6 months of ischaemic stroke: Adult, oral: 75
mg once daily
• Prevention of artherothrombotic events in acute coronary syndrome
without ST-segment elevation (given with aspirin): Adult, oral: Initially 300
mg, then 75 mg daily for up to 12 months
• Prevention of artherothrombotic events in acute myocardial infarction with
ST-segment elevation (given with aspirin): Adult, oral: 18–75 years: Initially
300 mg, then 75 mg for at least 4 weeks. >75years and over: 75 mg daily
• Prevention of atherothrombotic and thromboembolic events in patients
with atrial fibrillation (with aspirin) and for whom warfarin is unsuitable:
Adult, oral: 75 mg once daily","Abdominal pain, bleeding disorders (including gastro-
intestinal and intracranial), diarrhea, dyspepsia.","Anticoagulants, aspirin, NSAIDS, increase
bleeding risks. It increases action of some NSAIDSs, Phenytoin, Tamoxifen.
Proton pump inhibitor decrease clopidogrel effects."
PRASUGREL,Tablet: 5 mg and 10 mg,"Prevention of atherothrombotic events in patients with acute
coronary syndrome undergoing percutaneous coronary intervention, Patients
undergoing coronary angiography within 48 hours of admission for unstable
angina or NSTEMI, alternative to clopidogrel in certain patients undergoing
percutaneous coronary intervention","Active bleeding, history of stroke or
transient ischemic attack. Pregnancy: D, Breastfeeding: avoid, Hepatic
impairment: Use with caution in moderate impairment, increased risk of
bleeding. Avoid in severe impairment, renal impairment Use with caution—
increased risk of bleeding. Body weight less than 60 kg, discontinue at least
7 days before elective surgery if antiplatelet effect not desirable, elderly,
patients at increased risk of bleeding(e.g. from recent trauma, surgery,
gastrointestinal bleeding, or active peptic ulcer disease)","• In combination with aspirin for the prevention of atherothrombotic events
in patients with acute coronary syndrome undergoing percutaneous
coronary intervention: Adult, oral: 18–74 years :body-weight up to 60 kg:
Initially 60 mg for 1 dose, then 5 mg once daily usually for up to 12 months.
body-weight ≥60 kg: Initially 60 mg for 1 dose, then 10 mg once daily usually
for up to 12 months. ≥75 years: : Initially 60 mg for 1 dose, then 5 mg once
daily usually for up to 12 months.
• Patients undergoing coronary angiography within 48 hours of admission for
unstable angina or NSTEMI: Adult, oral: Initially 60 mg, to be administered
at the time of percutaneous coronary intervention to minimize the risk of
bleeding, maintenance dose of 10 mg or 5 mg daily should then be selected
as appropriate.
• Alternative to clopidogrel in certain patients undergoing percutaneous
coronary intervention: Adult, oral: 60 mg as a single dose","Anemia, gastro-intestinal hemorrhage, hematoma,
hematuria, hemorrhage, intracranial hemorrhage, rash","More chance hypersensitivity reaction while
administered with thienopyridines (e.g. clopidogrel)"
TICLOPIDINE,Tablet: 250 mg,"Coronary artery stent thrombosis (prevention), stroke","Neutropenia,
thrombocytopenia,
hemostatic disorder or active bleeding, severe hepatic impairment, history
of either thrombotic thrombocytopenic purpura (TTP) or aplastic anemia.
Pregnancy: B. Breast feeding: avoid. Hepatic impairment: caution, avoid in
severe hepatic impairment. Monitor Complete blood count, Liver function
test prior to initiation of treatment and every 2 weeks for the first 3 months.
May cause lifethreatening hematologic events, inclusing neutropenia,
agranulocytosis, thrombocytopenia purpura and aplastic anemia.","• Coronary artery stent thrombosis (prevention): Adult, oral: 250 mg twice a
day with aspirin for 30 days.
• Stroke: adult, oral: 250 mg twice daily with food.","Diarrhea, elevated alkaline phosphatase and aspartate
aminotransferase, nausea, dyspepsia, rash, neutropenia, purpura","Concurrent use of other anticoagulant drugs
increases the incidence of bleeding"
ETHAMSYLATE,Tablet: 500 mg,"Blood loss in menorrhagia, post-partum bleeding, post abortion
bleeding.","Pregnancy or breastfeeding woman;
Category B. Avoid excess dosage.The drug should be used with caution if
patient develops fever with treatment, non-cancerous growths fibroids in
uterus and, porphyria","Oral, adult: 500 mg 4 times daily
during menstruation.","Headache, rashes, hypotension",
TRANEXAMIC ACID,Tablet: 500 mg,"Menorrhagia, epistaxis, thrombolytic overdose, hereditary
angioedema, prophylaxis of hereditary angioedema.","Severe renal impairment (CrCl<1.5 mg/dl)
and thromboembolic disease. Caution in renal impairment and pregnancy","• Menorrhagia (initiated when menstruation started): oral, adult: 1 g 3 times
daily for up to 4 days, maximum 4 g daily.
• Local fibrinolysis: adult, oral: 15-25 mg/kg 2-3 times daily. Epistaxis: oral,
adult: 1 g 3 times a day for 7 days.
• Hereditary angioedema: oral, adult: 1–1.5 g 2–3 times a day, for short-term.
Patient information: Drug shouldn’t be used in combination with hormonal
contraceptives (birth control pills, patches, rings, injection). Do not take for
more than 5 days in a row.","Nausea, vomiting, diarrhoea, disturbances in colour vision,
nose stuffiness",
DESMOPRESSIN,"Tablets: 100 mcg, 200 mcg. Injection: 4 mcg.","For bleeding control, diabetes insipidus, primary nocturnal
enuresis.","Hypersensitivity, pseudo Von Willebrand’s
disease, cardiac insufficiency, angina pectoris, hypertension, renal
impairment, hypertension and cardiovascular disease. Rhinitis or Upper
respiratory tract infection can decrease the effectiveness of intranasal
preparation","• Hemophilia A/ Von Willebrand’s disease: Intranasal (adults and children) 1
spray (150 mcg) in each nostril (if >50 kg), in one nostril (if <50 kg)
• Diabetes insipidus diagnosis: subcutaneous or intramuscular, adult and
child, 2 mcg; Treatment: subcutaneous, intramuscular or intravenous, adult:
1-4 mcg daily, child: 400 nanogram.
• Renal function testing: subcutaneous or intramuscular, adult and child: 2
mcg","Fluid retention, headache, nausea, vomiting, epistaxis,
allergic reaction. Less pressor activity, but still need for considerable caution
in renal impairment, cardiovascular disease and hypertension.","Chlorpropamide, clofibrate or carbamazipine
may enhance antidiuretic response to desmopressin. Demeclocycline,
lithium, norepinephrine, alcohol may diminish the antidiuretic response to
desmopressin."
CALCIUM,"Tablets: 1.25 g calcium carbonate (equivalent to
500 mg calcium); Injection: 500 mg/5 ml, 1 g/10 ml (as calcium gluconate)
and 100 mg/10 ml (as calcium chloride)","Hypocalcemia in tetany, osteoporosis","Hypercalcemic states, do not use if allergic
to any ingredients of calcium preparations","• Supplement: 1-2 g between meals; daily requirement varies with the age and
is greater in childhood, pregnancy, lactation and old age
• Acute hypocalcaemia: 1-2 g by slow intravenous injection","Constipation, bradycardia, cardiac arrhythmia, hypotension
and irritation after parenteral administration","Reduce absorption of ciprofloxacin,
tetracycline, iron, bisphosphonates"
PHOSPHATES,"Tablet: Potassium phosphate 126 mg with Sodium
phosphate 67 mg; Potassium phosphate 250 mg with Sodium phosphate 160
mg; Potassium phosphate 250 with Sodium phosphate 298 mg",Treatment of hypophosphatemia,"Hyperphosphotemia,
hyperkalemia,
hypocalcemia, hypomagnesemia",,"Diarrhoea, nausea, vomiting, fluid retention, and
hypocalcaemia",
SODIUM FLUORIDE,Tablet: 2.2 mg; Mouth wash: 0.05% and 0.2%,Prevention of dental caries,"Infants under 6 months of age, advisable
to institute artificial fluoridation in areas with drinking water containing less
than 700 μg/l (0.7 ppm)","• Water content less than 0.3 ppm: child up to 6 months none; 6 months-3
years 250 μg daily; 3-6 years 500 μg daily; over 6 years 1 mg daily;
• Water content 0.3-0.7 ppm: child up to 3 years none; 3-6 years 250 μg daily,
over 6 years 500 μg daily;
• Prevention of dental caries: as oral rinse, child over 6 years 10 ml 0.05%
solution daily or 10 ml 0.2% solution weekly","White flakes on teeth with recommended doses; Yellowish
brown discoloration of teeth with more than recommended doses",
ZINC,Tablets: 10 mg and 20 mg,"Zinc deficiency, diarrhoea in children (rota virus infection),
adjunct to vitamin A therapy","Must be taken for 2-3 months to be
effective. Used with caution in acute renal failure","Adjunct to oral rehydration solution in acute diarrhoea,
• Under 6 months: 10 mg (elemental zinc) daily for 10 days;
• 6 months – 5 years: 20 mg daily for 10 days","Dyspepsia, abdominal pain, headache, nausea, vomiting,
gastritis","Decreases absorption of floroquinolones;
absorption of zinc is reduced when taken with dietary products, caffeine"
VITAMIN A (RETINOL),"Capsules: 200,000 U; Soft gel capsules:
200,000 U (retinol) and 40 U (DL-alpha-tocopherol or tocopheryl acetate)","Deficiency states, prophylaxis in high risk subjects, steatorrhea,
severe biliary obstruction, cirrhosis of liver or following total gastrectomy,
severe ocular damage","Hypersensitivity to vitamin A,
malabsorption syndrome, hypervitaminosis A, pregnancy, breastfeeding,
impaired renal function, children, hepatic disease, alcoholism, hepatitis","• Treatment of xerophthalmia: infants (6-11 months) 100,000U (3 drops) on
diagnosis, repeated next day and then after one month; child over one year
and adult (except women of child-bearing age) 200,000 units on diagnosis,
repeated next day and then after one month
• Prevention of vitamin A deficiency: child age 6 months to 5 years, 200,000
U every 6 months
• Measles: 200,000 U on diagnosis, repeated next day
• Prolonged diarrhoea of more than 14 days: 200,000 U on diagnosis
• Newly delivered mothers: 200,000 U at delivery or in the first 6 weeks
• Severe malnutrition: 200,000 U on diagnosis","Hypervitaminosis, fatigue, irritability, mental change,
anorexia, nausea, vomiting, GI upset","Mineral oil, cholestyramine, colestipol decrease
absorption of Vitamin A
Patient information: Refer to prescriber upon development of adverse effects"
VITAMIN D3 (CALCITRIOL),Capsule: 0.25 μg and 0.5 μg; Injection: 1 μg/ml,"Hypocalcaemia with chronic renal disease, psoriasis,
renal dystrophy, prevention and treatment of rickets, post menopausal
osteoporosis","Hypersensitivity, hyperphosphataemia,
hypercalcaemia, Pregnancy, breastfeeding, renal calculi","• Hypocalcaemia (Stage 5 chronic kidney disease): Children > 5 yrs and
adults, oral, 0.25 μg/day, Children 1-5 year, oral, 1-5 μg/day; Rickets, oral,
1 μg/day,
• Osteoporosis prophylaxis in corticosteroid therapy: oral, 0.5-1 mcg/day","Drowsiness, headache, palpitations, Hypertension,
photophobia, hypercalcemia, myalgia, arthralgia, weakness, pain in injection
site","Hypercalcaemia may occur if thiazide
diuretics, calcium supplements are concomitantly used; cardaic dysarrythmia
may occur with concomitant use of cardiac glycosides, verapamil
Patient information: Avoid over the counter products containing calcium,
potassium, sodium; maintain adequate fluid and water intake"
VITAMIN E (TOCOPHEROL),"Capsule: 100 IU, 200 IU, 400 IU, 500 IU, 600
IU and 1000 IU","Vitamin E deficiency states, impaired fat absorption, hemolytic
anemia in premature neonates, prevention of retrolental fibroplasias, sickle
cell anemia, supplementation of malabsorption syndrome","Pregnancy, anemia, breastfeeding,
hypoprothrombinaemia.","Deficiency states: adult, oral, 60-75 IU/day, child, oral, 1
IU/day","Headache, fatigue, increased risk of thrombophlebitis,
cramps, diarrhea, gonadal dysfunction, weakness","Increases actions of oral anticoagulants,
concomitant use of cholestyramine, sucralfate decrease absorption of
vitamin E"
VITAMIN B1 (THIAMINE),"Tablets: 50 mg, 100 mg, 250 mg and 500 mg, 20
mg (enteric coated); Injection: 100 mg/ml","Vitamin B1 deficiency, polyneuritis, cheilosis, beri-beri, Wernicke-
Korsakoff syndrome, pellagra, metabolic disorders","Hypersensitivity, pregnancy
Dosage schedule: Adult, oral (males) 1.2-1.5 mg, (females) 1.1 mg, (pregnancy)
1.4 mg, (breast feeding): 1.4 mg; child, oral-0.5-0.9 mg; infant, oral 0.2 mg","Adult, oral (males) 1.2-1.5 mg, (females) 1.1 mg, (pregnancy)
1.4 mg, (breast feeding): 1.4 mg; child, oral-0.5-0.9 mg; infant, oral 0.2 mg","Weakness, restlessness, pulmonary edema, hypotension,
collapse, angioneurotic edema, cyanosis, hemorrhage
Patient information: About the necessary foods to be included in diet: yeast,
beef, liver legumes, whole grains.",
VITAMIN B2 (RIBOFLAVIN),"Tablets: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg and
250 mg","Vitamin B2 deficiency, polyneuritis, cheilosis, migraine and
prophylaxis","Hypersensitivity to vitamin B2, pregnancy.","Adult- 5-30 mg/day, child>12 yr: PO 3-10 mg/day then 0.6
mg/1000 calories ingested; Migraine porphylaxis: adult- 400 mg/day for
three months",Yellow discoloration of urine,"Decrease action of tetracyclines, may cause
false elevations of urinary catecholamines
Patient information: Urine may turn bright yellow; Avoid alcohol"
VITAMIN B3 (NIACIN),"Tablets: 50 mg, 100 mg, 250 mg and 500 mg
(niacin); Tablets: 100 mg and 500 mg (niacinamide)","Pellagra, hyperlipidemias (types 4, 5), peripheral vascular
disease","Pregnancy, breastfeeding, hypersensitivity,
peptic ulcer, hepatic disease, hemorrhage, severe hypotension, glaucoma,
coronary artery disease, diabetes mellitus, gout, schizophrenia. Assess
cardiac status, nutritional status, CNS symptoms, Niacin deficiency,
Hyperlipidemia","Pellagra: adult, up to 500 mg daily in divided doses.","Paraesthesia, headache, dizziness, anxiety, Postural
hypotension, vasovagal attacks, dysrhythmias, vasodilation, blurred vision,
ptosis, jaundice, hepatotoxicity, hepatitis, glycosuria,","When combined with statins, either increases
the toxicity of the other: increase risk of rhabdomyolysis. Cholestyramine,
erythromycin, insulin decrease the blood level of niacin.
Patient information: Flushing and increase in feelings of warmth will occur
several hours after taking medicine; remain recumbent if postural hypotension
occurs; abstain from alcohol if product is prescribed for hyperlipidemia;
avoid sunlight if lesions are present"
VITAMIN B6 (PYRIDOXINE),"Tablets: 10 mg, 25 mg, 50 mg and 100 mg; 100
mg (extended release); Injection: 100 mg/ml; Capsules: 150 mg (extended
release)","Vitamin B6 deficiency, seizures, isoniazid therapy, oral
contraceptives, alcoholic polyneuritis","Pregnancy, breastfeeding, children,
Parkinson’s disease, patients taking levodopa should avoid supplemental
vitamins with >5 mg pyridoxine.","• Deficiency states: oral, 25–50 mg up to 3 times daily;
• Isoniazid neuropathy, prophylaxis: oral, 10 mg daily;
• Isoniazid neuropathy treatment: oral, 50 mg 3 times daily;
• Sideroblastic anemia: oral, 100–400 mg daily in divided doses","Paresthesia, flushing, warmth, lethargy, pain at injected
site.","Decrease the effects of levodopa
Patient information: Avoid vitamin supplements unless directed by prescriber;
increase meat, bananas, potatoes, lima beans, whole grains, and cereals in
diet"
VITAMIN B9 (FOLIC ACID),"Tablets: 0.1 mg, 0.4 mg, 0.8 mg, 1 mg and 5 mg;
Injection: 5 mg/ml and 10 mg/ml","Megaloblastic or macrocytic anemia caused by folic acid
deficiency; hepatic disease, alcoholism, hemolysis, intestinal obstruction,
pregnancy to reduce risk for neural tube defects","Pregnancy, anemia other than
megaloblastic/macrocytic anemia, vit B12 deficiency anemia, uncorrected
pernicious anemia.","• Treatment of folate-deficiency, megaloblastic anemia: oral, adult, 5 mg
daily for 4 months (in pregnancy continued to term); up to 15 mg daily may
be necessary in malabsorption states;
• Prevention of first occurrence of neural tube defects: oral, adult, 400–
500 micrograms daily before conception and during the first 12 weeks of
pregnancy;
• Prevention of recurrence of neural tube defects: oral, adult, 5 mg daily from
at least 4 weeks before conception until 12th week of pregnancy.","Confusion, depression, excitability, irritability, anorexia,
nausea, pruritus, rash, erythema, bronchospasm, anaphylaxis","Folic acid by estrogen, hydantoins,
carbamazepine, glucocorticoids, decreased levels of methotrexate,
sulfonamides, sulfasalazine, trimethoprim
Patient information: Urine will turn bright yellow; alter nutrition to include
high folic acids"
VITAMIN B12 (COBALAMIN),"Injection: 1 mg/ml (cyanocobalamine), 1 mg/ml
(hydroxycobalamine); Tablets: 50 μg","Vitamin B12 deficiency states, malabsorbtion, pernicious anemia,
stomach or lower ileal resection; macrocytic anemia","Hypersensitivity to Vitamin B12, uremia,
folate deficiency, concurrent infections, iron deficiency, renal dysfunction.
Parenteral products should be used when deficiency is due to malabsorption.","• Vitamin B12 deficiency of dietary origin: oral- adult, 50-150 μg /day
(cyanocobalamin), child, 25-50 μg, twice daily; intramuscular injection-
initially 1 mg repeated 10 times at intervals of 2-3 days, maintenance 1 mg
every month;
• Pernicious anaemia and other macrocytic anaemias without neurological
involvement: intramuscular injection, initially 1 mg (hydroxocobalamin)
repeated 5 times at intervals of 2 days, then 1 mg every 3 months
Parenteral preparation should be used until hematologic remission develops
and then should be switched to oral preparations","Dizziness, memory impairment, restlessness, hypertension,
chest pain, tachycardia, dry throat, eye redness, diarrhea, dyspepsia,
thrombocytosis, hypokalemia, pain at injection site","Chloramphenicol and antineoplastics
may decrease hematologic response to B12; Colchicine, aminoglycosides,
aminosalicylic acid, cimetidine, excess intake of alcohol or vitamin C may
decrease oral absorbtion or effectiveness of B12
Patient information: Patient should be encouraged to comply with diet
recommendations of heath care professional."
VITAMIN C (ASCORBIC ACID),Tablet: 50 mg,"Vitamin C deficiency, scurvy, delayed wound, bone healing,
chronic disease; urine acidification; before gastrectomy; dietary supplement","Tartrazine, sulfite sensitivity; glucose-6-
phosphate deficiency. Pregnancy, gout, diabetes, renal calculi.","• Prophylaxis of scurvy: oral, 25–75 mg daily;
• Treatment of scurvy: oral, not less than 250 mg daily in divided doses
Patient information: Addition of citrus fruits; avoid smoking","Headache, insomnia, dizziness, fatigue, flushing, nausea,
vomiting, diarrhea, anorexia, heartburn, cramps, polyuria, hemolysis",
ACETAZOLAMIDE,"Tablet: 125 mg and 250 mg; Powder for injection:
500 mg; Extended release capsule: 500 mg; Eye drops: 2%","Open-angle glaucoma, angle-closure glaucoma (preoperatively
if surgery delayed), secondary glaucoma, acute altitude sickness, CHF, drug
induced edema","Hypersensitivity to sulfonamide, severe renal
disease, hepatic disease, electrolyte imbalance (hyponatremia/hypokalemia),
hyperchloremic acidosis, addison’s disease, adrenocortical deficiency,
cirrhosis, long-term use in non-congestive angle-closure glaucoma. Not
recommended in pregnancy (C) and lactation: , hypercalciuria, diabetes,
respiratory acidosis, pulmonary obstruction, emphysema and COPD,
concomitant high dose aspirin.","• Angle closure glaucoma: per oral/intravenous- 250 mg 24hr and 250 mg BD
for short term therapy.
• Open-Angle glaucoma: per oral/intravenous – 250 mg/day in divided doses
for amounts of more than 250 mg or 500 mg BD (max 1 g/day)","Confusion, convulsions, cholestatic jaundice, drowsiness,
malaise, metallic taste, metabolic acidosis","Increases action of amphetamines, phenytoin,
procainamide, quinidine, anticholinergic; increases toxicity of salicylate and
cyclosporine; causes cardiac toxicity if hypokalemia develops with arsenic
trioxide, cardiac glycoside.
Patient’s information: May impair alertness and/or physical coordination."
AMILORIDE HYDROCHLORIDE,Tablet: 5 mg,"Oedema, CHF/HTN/Thiazide induced hypokalemia","Hyperkalaemia, Addison’s Disease, Renal
failure (if CrCL<10), Anuria, Diabetic nephropathy. Pregnancy, breast-feeding,
children, elderly, dehydration. Should be used with caution in patients with
diabetes mellitus, mild renal impairment.","• Oedema (used alone): per oral: initially 10 mg daily in 1 or 2 divided doses,
adjusted according to response (maximum 20 mg daily).
• Oedema (in combination with a thiazide or a loop diuretic): per oral: initially
5 mg daily, increasing to 10 mg daily if necessary (maximum 20 mg daily).
• CHF/HTN/Thiazide induced hypokalemia: 5-10 mg/day PO q day or divided
every 12 hour
• Renal impairment: If CrCl 10-50 ml/min: 50% normal dose; If CrCl<10 ml/
minute: not recommended","Hyponatremia, postural hypotension, diarrhoea, loss of
appetite, dizziness.","When combined with lithium: increases toxicity
Patient information: Take with food. To rise slowly from sitting to standing
to avoid orthostatic hypotension.To avoid driving and using machineries if
dizziness occurs. To avoid potassium-rich food."
CHLORTHALIDONE,"Tablet: 15 mg, 25 mg, 50 mg and 100 mg","Hypertension, ascites due to cirrhosis in stable patients (under
close supervision), oedema due to nephrotic syndrome, mild to moderate
chronic heart failure, nephrogenic diabetes insipidus, partial pituitary
diabetes insipidus.","Hypersensitivity to it or sulfonamides,
anuria. Pregnancy (B/D possible hazards include fetal or neonatal jaundice,
thrombocytopenia). Lactation not recommended.","• Hypertension: 12.5- 25 mg daily; per oral, dose to be taken in the morning,
increase if necessary to 50 mg daily.
• Edema: 50-100 mg/day PO or 100 mg PO every other day; not to exceed
200 mg/day.
• Mild to moderate heart failure: 25–50 mg daily; per oral, dose to be taken
in the morning, then increased if necessary to 100–200 mg daily, reduce to
lowest effective dose for maintenance.
• Nephrogenic diabetes insipidus |Partial pituitary diabetes insipidus:
Initially 100 mg per oral twice daily then reduced to 50 mg daily.","Hypotension, vasculitis, photosensitivity, phototoxicity,
electrolyte abnormalities, hyperglycemia, hyperuricemia, constipation,
diarrhea, loss of appetite, nausea, vomiting, spasticity, restlessness, dizziness,
headache, paresthesia, cardiac dysrhythmia (rare), pancreatitis (rare)","Aminolevulinic acid oral/topical +
Chlorthalidone-increases toxicity by pharmacodynamic synergism.
Amisulpride+Chlorthalidone:- Pharmacodynamic synergism, risk of
hypokalemia. Cisapride+Chlorthalidone: Contraindicated .Risk of prolonged
QTc interval. Tretinoin topical+ Chlorthalidone: Increased phototoxicity.
Avoid concurrent use with lithium (lithium dose reduction by 50% may be
necessary).
Patient information: Administered in the morning with food. Report to
treating doctor if dizziness and other mentioned side effects occurs."
EPLERENONE,Tablet: 25 mg and 50 mg,"HTN, heart failure post MI, renal impairment, hepatic impairment","Hypersensitivity. Serum potassium >5.5
mEq/L at initiation. Renal impairment if CrCl <50ml/min or Serum creatinine
>2 mg/dl in males or >1.8 mg/dl in females. Concomitant use with strong
CYP3A inhibitors. Pregnancy(B). Lactation –unknown. Hyperkalemia,
liver dysfunction, metabolic or respiratory acidosis, renal impairment,
hypersensitivity to spironolactone. Risk of hyperkalemia is higher in patients
with impaired renal function, proteinuria, diabetes and those concomitantly
treated with ACEIs and ARBs, NSAIDS and moderate CYP3A inhibitors.","• HTN: Initial 50 mg PO qDay; may increase to 50 mg PO every 12 hour; may
take up to four weeks for full therapeutic response; hyperkalemia may134
NNF 2018
occur with doses >100mg/day
• Heart failure post MI: Initial 25 mg PO qDay; may titrate to maximum of 50
mg once daily within 4 weeks as tolerated (Dose adjusted may be required
based on potassium levels).","Hyperkalemia, increased risk of hyperkalemia in presence
of renal dysfunction, dizziness, fatigue, albuminuria, abdominal pain","Itraconazole and Nefazodone and Saquinavir:
will increase the level or effect of eplerenone by affecting hepatic/intestinal
enzyme CYP3A4 metabolism. May increase the risk of hyperkalemia and
hypotension.
Patient’s information: Report to your treating doctor if awareness of heart
beat (palpitation) occurs and all other mentioned side effects occurs. Do not
use other medications without consulting registered doctor."
FUROSEMIDE,"Injection: 10 mg/ml in 2 ml ampoule; Tablet: 20
mg and 40 mg","Edema, heart failure, hypertension resistant to thiazide, fluid
overload in AKI/CKD, Acute Pulmonary edema/hypertensive crisis/increased
intracranial pressure","Renal failure with anuria, comatose
or precomatose states associated with liver cirrhosis, dehydration,
hyperkalemia, hypovolemia, severe hyponatremia. Pregnancy(C).Lactation:
drug excreted into breast milk; use with caution; may inhibit lactation. In
patients with liver cirrhosis, hypotension, elderly (reduce dose), oliguria,
renal and hepatic impairment and prostatic enlargement.","• Edema: initially 40 mg in the morning, maintenance 20-40 mg daily,
increased in resistant edema to 80 mg daily; child 1-3 mg/kg daily. Refractory
CHF may necessitate larger doses.
• Hypertension resistant: 20-80 mg PO divided every 12 hour
• Acute Pulmonary edema/Hypertensive crisis/Increased intracranial
pressure: 0.5 mg/kg (or 40 mg) IV over 1-2 minutes; may be increased to 80
mg if there is no adequate response within 1 hour; not to exceed 160-200
mg/dose.
• Hyperkalemia in Advanced Cardiac Life Support (ACLS): 40-80 mg IV.
• Hypermagnesemia in ACLS: 20-40 mg IV q3-4hr PRN.","Hypokalemia, hyponatremia, tinnitus, reversible or
permanent hearing impairment, rashes, loss of appetite, vomiting, diarrhea,
constipation, hyperuricemia gout.","Patients receiving cardiac glycoside,
furosemide predisposes the patient to digitalis toxicity principally due to
hypokalemia. The hypotensive effects enhanced when given concomitantly
with ACE inhibitors, alcohol, alpha blockers, general anesthetic agents,
angiotensin-II receptor antagonists, beta blockers and calcium channel
blockers. Concomitant administration of furosemide and aminoglycosides
may result in increased incidence of ototoxicity and nephrotoxicity. Cisapride
+ Furosemide:-C/I; Risk of prolonged QTc interval.
Patient information: To take high potassium diet or potassium replacement
with drug as hypokalemia is seen. Rise slowly from lying or sitting position
because orthostatic hypotension may occur, to take with food or milk for GI
symptoms, to use sunscreen or protective clothing to prevent photosensitivity."
HYDROCHLORTHIAZIDE,"Tablet: 12.5 mg, 25 mg and 50 mg","Edema associated with mild congestive heart failure, hepatic
cirrhosis, nephritic syndrome, chronic renal failure, acute glomerulonephritis,
hypertension, nephrogenic diabetes mellitus, calcium nephrolithiasis.","Hypersensitivity, anuria, hyponatremia,
hypercalcemic states (hyperparathyroidism, malignancies), hypokalemia,
hyperuricemia, contraindicated in patients hypersensitive to sulfonamide,
polymorphic ventricular tachycardia. Pregnancy(B), Lactation: drug excreted
in breast milk. Use with caution in gout, elderly, may unmask latent diabetes
mellitus, glucose intolerance, history of MI, DM, fluid or electrolyte imbalance,
hypercholesterolemia, SLE.","• Hypertension: 12.5 mg daily per oral (can be increased up to 25-50mg)
administered in morning or in twice daily dose (second dose should be
before 6pm)
• Edema: 25-50 mg per oral initially, maintenance dose 25-50 mg on alternate
days.","Anaphylaxis, anorexia, confusion, dizziness, extracellular
fluid volume depletion, hypotension, hypokalemia, hyponatremia,
hyperglycemia, hypercalcemia, hyperuricemia, hyperlipidemia, erectile
dysfunction, CNS and GI disorders are less common or rare, hepatotoxicity,
cholesterol.","Amphotericin B and Corticosteroids increase
the risk of hypokalemia, Torsade’s de pointes and fatal ventricular fibrillation
when used along with Quinidine. Decreased effects of anticoagulants,
uricosuria drugs, sulfonyl ureas and increased effects of loop diuretics,
anesthetics, digitalis, lithium when concomitantly used.
Patient’s information: To rise slowly from lying or sitting position. To report if
any signs of electrolyte imbalance, confusion occurs."
INDAPAMIDE,"Tablet: 2.5 mg (immediate release), 1.5 mg
(sustained release)","Hypertension, congestive heart failure","Avoid in severe hepatic impairment, renal
impairment. Use caution in acute porphyria, hypotension, diabetes mellitus,
hyperuricemia, gout, SLE, hepatic and/or renal impairment. Pregnancy
(B). Breast feeding: avoid. Efficacy and safety of the drug has not been
established in children","• Essential hypertension: oral (using immediate-release), adult: 2.5 mg daily,
dose to be taken in the morning
• oral (using sustained release), adult: 1.5 mg daily, may increase at 4 week
interval up to 5 mg, dose to be taken in the morning.
• Congestive heart failure: oral (using immediate-release), adult: 2.5 mg daily,
dose to be taken in the morning","Skin rash, hypokalemia, anorexia, diarrhea, orthostatic
hypotension, palpitation.","Avoid if hypersensitivity to sulfonamides. Avoid
concurrent use with arrhythmogenic drugs such as amisulpride, amitriptyline,
artemether/ lumefantrine, astemizole, Chlorpromazine, cisapride,
clarithromycin, disopyramide, desimipramine, fluconazole, ketoconazole,
itraconazole, nilotinib, octreotide, haloperidol. Avoid use with other diuretics
due to risk of hypokalemia."
METOLAZONE,"Tablet: 2.5 mg, 5 mg and 10 mg","Hypertension, Edema","Hypersensitivity to it or sulfonamides.
Anuria, Hepatic coma or precoma. Acute porphyrias. Pregnancy (drug crosses
placenta; hypokalemia, hypoglycemia, jaundice, thrombocytopenia and
hyponatremia reported in fetus following maternal use of thaizide diuretics)
Lactation: The amount present in milk is too small to be harmful. Large doses
may suppress lactation. Use with caution in DM, hypercholesterolemia,
hyperuricemia or gout, hypotension, SLE, previously sympathectomy, liver
disease.","• Oedema: 5–10 mg daily, dose to be taken in the morning, dose may be
increase in resistant oedema; increased if necessary to 20 mg daily;
maximum 80 mg per day.
• Hypertension: initially 5 mg daily, dose to be taken in the morning;
maintenance 5 mg once daily on alternate days","Chest pain, chills, dizziness, drowsiness, electrolyte
abnormalities, glucosuria, hyperuricemia, hepatotoxicity","Aminolevulinic acid oral/topical + Metolazone-
increases toxicity. Amisulpride+Metolazone, risk of hypokalemia.
Cisapride+Metolazone: Contraindicated .Risk of prolonged QTc interval.
Tretinoin topical+ Metolazone: Increased phototoxicity.
Patient’s information: Tablets may be crushed and mixed with water
immediately before use."
SPIRONOLACTONE,"Tablet: 25 mg, 50 mg and 100 mg","Edema and ascites in cirrhosis of liver, nephrotic syndrome,
congestive heart failure, primary hyperaldosteronism.","Hyperkalemia, hyponatremia, addison
disease,moderate renal impairment. Elderly (reduce dose), diabetes mellitus,
renal and hepatic impairment, pregnancy, breastfeeding. Spironolactone
should be cautiously used when aforementioned drugs are to be used
concomitantly. Serum level of Blood Urea Nitrogen (BUN) and K+ should be
monitored regularly.","• Edema: In adult:100-200 mg per oral daily, increased up to 400 mg daily in
resistant edema; maintenance dose 25-200 mg daily. (child) 1-3 mg/kg daily
in 1- 2 divided doses.
• Primary hyperaldosteronism: per oral (adult) 400 mg daily for 3-4 weeks,
preoperative management: 100-400 mg daily; if not suitable for surgery,
lowest effective dose is used as maintenance therapy.
• Adjunct in severe heart failure: per oral (adult) usually 25 mg daily.","Hyperkalemia, metabolic acidosis (in cirrhotic patients),
gynecomastia, impotence, decreased libido, hirsutism, menstrual irregularity,
diarrhea, gastritis, gastric bleeding, breast cancer risk is increased in chronic
use.","Hepatic CYP3A4 isoform inhibitors like
macrolide antibiotics, (clarithromycin), azole antifungals (ketoconazole,
itraconazole), protease inhibitors(indinavir,ritonavir) may induce dangerous
hyperkalemia by inhibiting spironolactone catabolism.
Patient information: Avoid foods with high potassium content, oranges,
bananas, salty food."
TORSEMIDE,"Tablet: 10 mg, 20 mg and 100 mg","Congestive heart failure, Chronic renal failure, Hepatic cirrhosis,Hypertension.","Known hypersensitivity to torsemide or
to povidone, Anuria, Hepatic Coma. Pregnancy & Lactation- No available
data. Use with caution in DM, fluid or electrolyte imbalance (hypokalemia,
hyponatremia), hyperglycemia, hyperlipidemia, hyperuricemia or gout, severe
liver disease with cirrhosis and ascites.","• CHF: 10-20 mg PO/IV mg once daily initially, doubled until desired diuretic
effect is achieved, individual dose not to exceed 200 mg.
• CRF: 20 mg PO/IV OD initially; doubles until desired diuretic effect is
achieved; individual dose not to exceed 200 mg.
• Hepatic cirrhosis: 5-10 mg PO/IV once daily initially with aldosterone
antagonist or potassium sparing diuretic; individual dose not to exceed 40
mg.
• Hypertension: 2.5-5 mg/day PO initially; increased to 10 mg/day PO in 4-6
weeks PRN","Headache, Electrolyte imbalance, Dizziness, Rhinitis,
Constipation, Cough, Diarrhoea, Dyspepsia
Patient’s information: Rise slowly from lying or sitting position. Limit alcohol
use. Take the medication with milk or food to limit GI symptoms. Use
sunscreen, protective clothing to prevent sunburn.",
TRIAMTERENE,Tablet: 50 mg,"Edema, potassium conservation with thiazides and loop
diuretics.","Addison’s disease, anuria, hyperkalemia.
Diabetic mellitus, elderly, gout, may causes blue fluorescence of urine.
Regular monitoring of blood K+ to check for hyperkalemia","Initially 15-250 mg daily, reducing to alternate days after 1
week, taken in divided dose after breakfast and lunch, lower initial dose when
given with other diuretics.","Hyperkalemia, nausea, vomiting, diarrhea, muscle cramps,
dizziness","When other K+ sparing diuretics are
concomitantly used dangerous hyperkalemia may develop.
Patient’s information: Avoid using high K+ diet like avocado, banana, dried
apricots etc."
DESMOPRESSIN,Tablet: 100 μg and 200 μg; Injection: 4 μg,"Diabetes insipidus, primary nocturnal enuresis, post-operative
polyuria or polydipsia, nocturia associated with multiple sclerosis.","Hyponatremia. In cardiac insufficiency,
renal impairment, conditions treated with diuretics, polydipsia in alcohol
dependence, psychogenic polydipsia. Asthma, cardiovascular disease,
cystic fibrosis, heart failure. If hyponatremia occurs therapy may be hold or
discontinued.","• Diabetes insipidus: adult and child, initially 300 μg per oral daily (in three
divided doses); maintenance: 300-600 μg daily in three divided doses;
range 0.2-1.2 mg daily. By injection in diabetes insipidus, for diagnosis
(subcutaneous or intramuscular adult and child, 2 μg; for treatment
(subcutaneous, intramuscular or intravenous) adult 1-4 μg daily, child 400
ng
• Primary nocturnal enuresis: Adult and child over 5 years: 200 μg at bedtime,
increased to 400 μg if lower dose not effective.
• Postoperative polyuria/polydipsia: adjust dose according to urine
osmolality.
• Renal function testing (subcutaneous or intramuscular): adult and child:
2 μg.","fluid retention, headache, nausea, vomiting, epistaxis,
allergic reaction.","Chlorpropamide/dobutamine increases effects
of desmopressin by pharmacodynamic synergism.
Patient’s information: Patients being treated for primary nocturnal enuresis
should avoid fluid overload and stop taking desmopressin during an episode
of vomiting or diarrhoea. Do not take excessive fluid while on therapy."
NITROFURANTOIN,Tablet: 50 mg and 100 mg,"UTI, cystitis, pyelonephritis, and postoperative infection of
urinary tract.","Hypersensitivity, infant under 1-month,
impaired renal function with estimated GFR <30 ml/min, pregnancy at term
(38-42 weeks), hepatic dysfunction. Gastritis patients, gastrointestinal
disease, diabetes. Pregnancy (B). Crosses placenta. Lactation: enters breast
milk; discontinue drug or do not nurse. Avoid long term use in elderly.","Adult 50-100 mg per oral tid/qid. Child: 3-6 mg/kg body
weight per oral in four divided doses.","Headache, dizziness, peripheral neuritis and neurological
effects, chest pain, leukopenia, blood dyscrasias, hemolytic anemia, GI
intolerance, nausea, diarrheas, anorexia","Probenecid increases levels of nitrofurantoin
Increases antagonistic effect of norfloxacin.
Patient’s information: Suggested to take medicine after meal to avoid gastric
irritation. Color of the urine can be brownish, not to worry. Tablets should
not be crushed. Protect from light."
BETHANECHOL,"Tablet: 5 mg, 10 mg, 25 mg and 50 mg",Urinary retention,"Hypersensitivity,
hyperthyroidism,
peptic ulcer, asthma, bradycardia, hypotension, AV Conduction defects,
CAD vasomotor instability, vagotonia, epilepsy, parkinsonism, obstructive
pulmonary disease, HTN. GI disturbances or anastomosis. Pregnancy (C),
Lactation: decision should be made whether to discontinue nursing or to
discontinue drug.","Urinary retention: 10-50 mg PO 3-4 times daily. Some
patients may require doses of 50-100 mg PO twice daily. Take 1 hour before
or 2 hours after meal.","Abdominal cramps, belching, bronchial constriction,
diarrhoea, flushing, headache, urinary urgency","Ambenonium: It increases effects of bethanechol
by pharmacodynamic synergism. Amitriptyline: Bethanechol increases
and amitriptyline decreases cholinergic cholinergic effects/transmission.
Flavoxate/ Solifenacin/Ipratropium: Bethanechol increases and flavoxate/
solifenacin/ Ipratropium decreases cholinergic effects/transmission.
Patient’s information: Take 1 hour before meal or 2 hour after meals"
FLAVOXATE,Tablet: 100 mg,Overactive bladder (OAB),"Obstructive uropathy, pyloric/duodenal
obstruction, ileus, GI bleeding, achalasia. Pregnancy (B). Lactation: not
known. Use caution in patients with glaucoma. May impair ability to perform
hazardous tasks. May cause ocular disturbances; advice patients of potential
effects.","OAB (indicated for dysuria, increased urinary frequency/
incontinence, nocturia, suprapubic pain, urinary incontinence, urinary tract
irritation, urinary urgency): 100-200 mg PO q6-8hr","Abdominal pain, Blurred vision, Confusion, Constipation,
Distubance in ocular accommodation, Drowsiness, Dry mouth, Dysuria,
Increased ocular tension, Vertigo.","Pramlintide+Flavoxate: either increases effects
of the other by pharmacodynamic synergism. Contraindicated. Synergistic
inhibition of GI motility. Secretin: Flavoxate decreases effects of secretin
by pharmacodynamic antagonism. (avoid or use alternative drug). Monitor
closely while using amilsulpride/amitriptyline/Clozapine/Chlorpromazine.
Patient’s information: Vertigo can occur."
MIRABEGRON,Tablet: 25 mg and 50 mg,Overactive Bladder (OAB),"Hypersensitivity, Pregnancy (C), Lactation:
unknown, discontinue nursing or the drug. May increase BP, Urinary
retention may occur with bladder outlet obstruction or with concomitant
antimuscarinic therapy. Angioedema of the face, lips, tongue and/or larynx
reported.","Indicated for OAB with symptoms of urge urinary
incontinence, urgency and urinary frequency: 25 mg PO qDay. 25 mg dose is
typically effective within 8 weeks. May increase to 50 mg PO qDay based on
individual efficacy and tolerability. Dosage modification in renal impairment:
Severe (Crcl-15-29ml/min) not to exceed 25 mg/day. ESRD-not recommended.","Elevated BP occurring predominantly in patients with
preexisting hypertension, dry mouth, nasopharyngitis, UTI, headache,
constipation, cystitis, back pain, arthralgia, Steven Johnson syndrome.","Monitor closely: while using amitriptyline/
codeine/metoprolol/tramadol- Mirabegron will increase the level or effect
of amitriptyline/codeine/metoprolol/tramadol, by inhibiting hepatic enzyme
CYP2D6 metabolism. Patient’s information: May take with or without food. Swallow whole with
water, do not chew, divide or crush tablet."
OXYBUTYNIN,"Tablet: 5 mg; Tablet extended-release: 5 mg, 10
mg and 15 mg; Syrup: 5 mg/ml",Overactive bladder (OAB),"Hypersensitivity, gastric or urinary
obstruction or retention, paralytic ileus, severe ulcerative colitis, uncontrolled
narrow –angle glaucoma. Use with caution in : Myasthenia gravis, tachycardia
secondary to cardiac insufficiency or thyroxicosis. Pregnancy/Lactation: NA.
In controlled angle closure glaucoma; mild to moderate ulcerative colitis,
hyperthyroidism; partial obstructive uropathy; benign prostatic hyperplasia.
hepatic and renal impairment. May aggravate symptoms of decreased
gastrointestinal motility in patients with autonomic neuropathy.","• OAB: Relief of symptoms (e.g. urge incontinence,frequency, urgency)
in patients with uninhibited neurogenic or reflex neurogenic bladder.
Immediate release: 5 mg PO twice/three times daily; not to exceed 5 mg PO
four times daily. Extended release: 5-10 mg/day PO; may be increased by 5
mg/day at weekly intervals; not to exceed 30 mg/day. Pediatric: Tab 5 mg,
Syrup: 5 mg/ml
• Detrusor overactivity: Bladder overactivity associated with a neurologic
condition (e.g. Spina bifida) ≥5 yrs (immediate release):5 mg PO every 12
hour;may be increased to 5 mg POq8hr. ≥ 6 yrs (Extended release):5 mg/
day PO initially;may be increased by 5 mg/day at weekly intervals; not to
exceed 20 mg/day.","Dry mouth, constipation, somnolence, nausea","Potassium chloride + oxybutynin. Avoid or
use alternate drug. Patients using drugs with extensive anti cholinergic
effects should avoid concomitant use with solid oral dosage forms of
potassium chloride. May use effervescent potassium preparations as
alternatives. Pramlintide + oxybutynin: Either increases effects of the other
by pharmacodynamic synergism. Contraindicated. Synergistic inhibition
of GI motility. Secretin: Oxybutynin decreases effects of secretin by
pharmacodynamic antagonism.
Patient’s information: May cause memory loss. Contact doctor if symptoms
do not improve with 2 weeks of initial use."
SOLIFENACIN,Tablet: 5 mg and 10 mg,"Overactive bladder (OAB), Urge incontinence","Urinary or gastric retention, uncontrolled
narrow angle glaucoma, severe hepatic impairment, hypersensitivity.
Pregnancy (C), Lactation: Avoid using drug or stop nurse. Bladder outflow
obstruction, controlled narrow angle glaucoma, decreased GI motility, renal
or hepatic impairment. Peripheral edema, exfoliative dermatitis, erythema
multiforme, elevated liver enzymes, hyperkalemia, muscular weakness, renal
impairment, GERD were noted after post marketing.",OAB: 5 mg PO OD; may be increased to 10 mg PO OD,"Dry mouth, Constipation, Abdominal Pain, Blurred Vision","Itraconazole: it will increase the level or effect of
solifencain by inhibiting hepatic/intestinal enzyme CYP3A4 metabolism(C/I)
Coadministration with solifenacin in hepatic/renal impairment may result
in potentially fatal adverse events. Use caution while using Ondansetron/
Ketoconazole/carbamazepine together with Solifencacin.
Patient’s information: Reports if there is headache, confusion, hallucinations
and somnolence."
TOLTERODIN,Tablet: 1 mg and 2 mg,"Overactive bladder, Urge incontinence","Urinary
or
gastric
retention,
Uncontrolled narrow angle glaucoma, hypersensitivity. Pregnancy(C),
Lactation: Unknown. Controlled narrow angle glaucoma, bladder outflow
obstruction, gastrointestinal obstruction, hepatic or renal impairment.
Caution with patients of myasthenia gravis. Reduce dosage of tolterodine
when coadministered with strong CYP3A4. Anaphylaxis and angioedema
necessitating hospitalization and emergency treatment reported with first or
subsequent doses.","OAB, urge incontinence: immediate release 2 mg PO every
12 hour, Extended release: 2-4 mg PO once daily","Dry mouth, blurred vision, constipation, dizziness,
drowsiness, dyspepsia","Carbamazepine will decrease the level or effect
of tolterodine. Clarithromycin will increase the level or effect of tolterodine
by affecting CYP3A4 metabolism.
Patient’s information: Report if dizziness/somnolence occurs. Do not drive or
operate heavy machinery until adjusted to therapy."
BAMBUTEROL,Tablet: 10 mg and 20 mg,"Bronchial asthma, COPD","Renal disorders, liver diseases, heart
diseases, diabetes, epilepsy, hyperthyroidism and hypertension, myocardial
insufficiency, history of seizures, heart disease. Pregnancy category B,
caution in lactation","Initially, 10 mg once daily at bed time, increased if
necessary after 1-2 weeks to 20 mg once daily; not recommended in children.","Muscle cramps, dizziness, headache, muscle tremor,
palpitation, ankle edema, hypokalemia.","Concomitant use of high dose of salbutamol
and corticosteroids or diuretics increases the risk of hypokalemia."
SALBUTAMOL,"Aerosol pressurized inhalation: 100 µg per
inhalation; Dry powder: 200 µg per dose; Injection: 50 µg and 500 µg/ml;
Oral Solution: Each 2 mg/5 ml; Tablets: 2 mg, 4 mg and 8 mg.","Bronchial asthma, COPD","Salbutamol must not be used to prevent
premature labour in the case of pre-eclampsia, placenta previa and bleeding.
Hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to
QT-interval prolongation, hypertension, pregnancy (high doses should be
given by inhalation because parenteral use can affect the myometrium and
possibly cause cardiac problems), breastfeeding. Monitor blood Glucose
(Ketoacidosis has been reported in Diabetes Mellitus following Intravenous
administration)","• By mouth: 4 mg (elderly and sensitive patient initially 2 mg) 3-4 times daily;
maximum single dose 8 mg (but unlikely to provide much extra benefit or to
be tolerated), child under 2 years 100 µg /kg 4 times daily; 2-6 years 1-2 mg
3-4 times daily; 6-12 years 2 mg
• By subcutaneous or intramuscular injection: 500 µg , repeated every 4
hours if necessary
• By slow intravenous injection: 250 µg repeated if necessary
• By intravenous infusion: initially 5 µg /minute, adjusted according to
response and heart-rate usually in range 3-20 µg /minute or more if
necessary
• By aerosol inhalation: 100-200 µg (1-2 puffs); for persistent symptoms up
to 3-4 times daily; child 100 µg (1 puff) increased to 200 µg (2 puffs) if
necessary. Prophylaxis in exercise induced bronchospasm, 200 µg (2 puffs);
child 100 µg (1 puff)
• By inhalation of a powder: 200-400 µg ; for persistent symptoms up to 3-4
times daily; child 200 µg. Prophylaxis in exercise-induced bronchospasm
(powder), 400 µg ; child 200 µg
• By inhalation of nebulized solution: adult and child over 18 months, chronic
bronchospasm unresponsive to conventional therapy and severe acute
asthma, 2.5 mg, repeated up to 4 times daily, increased to 5 mg if necessary,
child 2.5 mg increased to 5 mg if required.","Muscle cramps, dizziness, headache, muscle tremor,
palpitation, ankle edema, hypokalemia.","Concomitant use of high dose of salbutamol
and corticosteroids or diuretics increases the risk of hypokalemia."
TERBUTALINE SULFATE,"Aerosol pressurized inhalation: 250 µg dose;
Injection: 500 µg per ml; Tablets: 2.5 mg and 5 mg","Bronchial asthma, COPD","It must not be used to prevent
premature labour in the case of pre-eclampsia, placenta previa and bleeding.
Hyperthyroidism, myocardial insufficiency, arrhythmias, susceptibility to
QT-interval prolongation, hypertension, pregnancy (high doses should be
given by inhalation because parenteral use can affect the myometrium and
possibly cause cardiac problems), breastfeeding. Monitor blood Glucose
(Ketoacidosis has been reported in Diabetes Mellitus following Intravenous
administration). Tolerance develops
in patients receiving long term therapy; dose may have to be changed;
monitor rebound bronchospasm","• Oral: 2.5-5 mg 2-3 times daily; child 0.1 µg /kg 3 times daily.
• By subcutaneous, intramuscular or slow intravenous injection: 250-500 µg
up to 4 times daily; child <12 years 0.01µg /kg every 20 minutes 3 doses;
• By continuous intravenous infusion (as a solution containing): 3-5 µg /ml,
1.5-5 µg /minute for 8-10 hours, reduce dose for children.
• By aerosol inhalation: adults and children 250-500 µg (1-2 puffs), for
persistent symptoms up to 3-4 times daily.","Muscle cramps, dizziness, headache, muscle tremor,
palpitation, ankle edema, hypokalemia.","Increases hypertensive crisis with MAOIs.
Decreases the action of beta-blockers. The effect of terbutaline is increased
with green tea (large amounts)."
MONTELUKAST,"Tablet: 4 mg, 5 mg and 10 mg.","Chronic asthma in adults and children, seasonal allergic rhinitis,
bronchospasm prophylaxis.","Hypersensitivity. Pregnancy, breastfeeding,
children <6 yrs, acute attack of asthma, alcohol consumption, severe hepatic
disease, corticosteroid withdrawal, phenylketonuria, suicidal ideation,
depression.","Adult and child>15 yr: 10 mg/day in PM; child 6 -14 yrs: 5
mg chew tab/day in PM; child 2 – 5 yrs: 1 packet (4 mg) granules taken in PM","Dizziness, fatigue, headache, behavior change,
hallucinations, seizures, agitation, anxiety, Churg-Strauss syndrome.
Patient information: Avoid hazardous activities; dizziness may occur,
continue the use inhaled beta agonists if exercise-induced asthma.",
ZAFIRLUKAST,Tablet: 10 mg and 20 mg.,"Prophylaxis and chronic treatment of asthma in adults/children
>5yr, allergic rhinitis","Hypersensitivity, hepatic encephalopathy.
Pregnancy, breastfeeding, children, geriatric patients, hepatic disease,
Churg-strauss syndrome, acute bronchospasm. Adult patients carefully for
symptoms of Churg- Strauss syndrome; Liver function test.","Adult and children>yr: 20 mg twice daily; Child 5-11yr: 10
mg twice daily; Child >12 yr: 20 mg twice daily","Headache, dizziness, nausea, diarrhea, abdominal pain,
vomiting, hepatic failure, hepatitis, angioedema",Food decrease bioavailability.
SODIUM CROMOGLYCATE,Hard gelatin capsule: 20 mg,"Prophylaxis of asthma, allergic rhinitis, allergic conjunctivitis.","Known hypersensitivity. Pregnancy,
lactation, old age children
and used with caution in patients with cardiac,
hepatic and renal diseases","Inhalation of powder, adults and children, 20 mg 4 times
daily, increased in severe cases to 8 times daily.","Throat irritation and cough, nasal congestion, headache,
dizziness, arthralgia, rashes, bronchospasm
Patient’s information: The capsules are intended for use in an inhaler and
not to be swallowed. Sodium cromoglycate insufflation should be protected
from moisture. Nasal sol. blow nose, hold pump between fingers; if its use,
spray in air until fine mist occurs, Aerosol: take off cover mouthpiece, sake
gently, breathe out slowly, place mouthpiece in mouth, close mouth around
it, till head back, breathe in as inhaler, inhalation: Do not swallow sol, empty
ampule into power driven nebulizer as directed.",
EPHEDRINE HYDROCHLORIDE,Tablets: 30 mg,Reversible airways obstruction,"The drug should be used with caution
in patients with
hypertension, severe renal impairment and prostate
hypertrophy.","15-60 mg 3 times daily; child 3 times daily, up to 1 year: 7.5
mg, 1-5 years: 15 mg, 6-12 years: 30 mg.","Arrhythmias, insomnia, tremor, tachycardia.",
AMINOPHYLLINE,Tablet: 100 mg; Injection: 250 mg/10ml,"Bronchial asthma, COPD, Neonatal apnea.","Hyperthyroidism,
uncontrolled
arrhythmias. Patient of Age> 60 years, patient with liver disease. Should not
be given to the children under one year of age except in apnea of prematurity,
therapeutic dose is near the toxic dose so that give carefully, don’t give IM
or SC.","Adult: 100-300 mg three times a day; Injection: IV dose
6 mg /kg over 20 to 30 minutes as loading dose, then maintenance dose 0.4
to 0.7 mg/kg/hour depending on comorbidities; Child dose, loading dose: IV
5-6mg/kg, maintenance dose: IV 1-2 mg/kg/dose every 8 hours","Headache, dizziness, extra systoles, sinus tachycardia,
anorexia, nervousness, tremor","Additive CVS and CNS side effects can be seen
with sympathomimetic, elevated serum levels in patients receiving cimetidine,
beta blockers, erythromycin, allopurinol or oral contraceptive pills.
Patient information: Suggest patients to take a lot of water with this medicine."
DOXOFYLLINE,Tablet: 400 mg,"Asthma, COPD","Hypersensitivity, acute myocardial
infarction, hypotension. Use with caution in patients with hypoxemia,
hyperthyroidism, liver disease, renal disease, in those with a history of peptic
ulcer and in elderly.","Adult: 400 mg once daily or twice daily; Children: 12 mg/
kg/day","Headache, nausea, vomiting, sleeplessness, dizziness","Should not be administered together with
other xanthine derivatives, including beverages and foods containing caffeine"
THEOPHYLLINE,Tablet: 100 mg and 200 mg,"COPD, Bronchial asthma, Nocturnal asthma","Hyperthyroidism,
uncontrolled
arrhythmias. Patient of Age> 60 years, patient with liver disease. Should not
be given to the children under one year of age except in apnea of prematurity,
therapeutic dose is near the toxic dose so that give carefully, don’t give IM
or SC.Close monitoring
of the patient taking medicine should be done because the effective dose is
very close to the toxic dose.","• Adult: 200 mg bid .Dose can be increased after 1 week up to 300 mg bid,
Over 70 kg: 200-300 mg twice daily;
• Neonatal apnea: Loading dose: PO 5 mg/kg/dose, maintenance dose: PO
3-6 mg/kg/day in 3-4 divided doses; Child: >1 year
• Bronchospasm: PO 12-14 mg/kg/day in 3-4 divided doses (Max. dose 300
mg/day)","Nausea, vomiting, GI upset, headache, dizziness, convulsion","Never combine with ciprofloxacin, corticosteroids,
theophylline, erythromycin and cimetidine they may cause increase the level
of theophylline in the blood. Never combine with carbamazepine; phenytoin
and barbiturates they may cause decrease the level of theophylline in the
blood. Patient information: Suggest patients to take a lot of water with this medicine."
CODEINE PHOSPHATE,"Tablet: 15 mg, 30 mg and 60 mg","Non-productive cough, pain","In asthmatics, patients with decreased
respiratory reserve, patients who are allergic to codeine or oxycodone,
patients with history of drug abuse and drug seeking behavior (due to
abuse liability). It should be cautiously used in patients with severe prostatic
hypertrophy and hepatic disease; pregnancy, breastfeeding, COPD.","• Mild to moderate pain: 30-60 mg every 4 hours when necessary, to a
maximum of 240 mg daily; child 1-12 years, 0.5-1 mg/kg/dose every 6 hours
(Max. dose 60 mg/kg);
• Dry or painful cough: 15-30 mg 3-4 times daily. Child 5-12 years, 1-1.5 mg/
kg 4 times daily.","Nausea, constipation, drowsiness, confusion,
blurred vision, hypotension, bradycardia, respiratory depression on large
doses, physical dependence on prolonged use.","Codeine is used with extreme caution in patient
receiving MAO inhibitors, additive CNS depression occurs with alcohol,
antidepressants, antihistamines, sedative and hypnotics.
Patient information: Avoid driving or other activities requiring high alertnes"
BROMHEXINE,Tablets: 5 mg; Syrup: 4 mg/5 ml,Reduction of sputum viscosity in COPD patients.,"Not recommended for infants < 1 year,
peptic ulcer, severe hepatic /renal impairment. Should be used with caution in
pregnant and breastfeeding women. Since mucolytics may disrupt the gastric
mucosal barrier, bromhexine should be used with caution in patients with a
history of gastric ulceration. Clearance of bromhexine or its metabolites may
be reduced in patients with severe hepatic or renal impairment.","Oral: 8 to 16 mg three times daily; child 2-6 years 8 mg 2-3
divided dose daily; 6-12 years: 4-8 mg per dose three times daily.","Gastrointestinal side effects may occur occasionally with
bromhexine and a transient rise in serum aminotransferase values has
been reported. Other reported adverse effects include headache, vertigo
(dizziness), sweating and allergic reactions.","Should not be given with especially paracetamol
(if so chances of hepatitis is increased).
Patient information: Should be taken after meal."
CARBOCYSTEINE,Capsules: 375 mg; Syrup: 250 mg/5 ml,Reduction of sputum viscosity in COPD.,"Avoid use in pregnancy. It should be used
with caution by patients with a history of peptic ulceration. Should be
cautiously used in children under 2 years old.","750 mg 3 times daily initially; then 1.5 g daily in divided
doses; child 2-5 years 200-500 mg per day 2- 4 times divided dose daily, 6-12
years 300-750 mg 3 times divided dose daily.","Skin rashes, occasional gastro- intestinal irritation.",
PHENYLEPHRINE,"Tablet: 5 mg; Nasal spray: 0.125%, 0.25%,
0.5% and 1%","Nasal congestion associated with acute or chronic rhinitis,
common cold, and sinusitis","Patients with diabetes, hypertension,
ischemic heart disease, hepatic impairment, renal impairment. Stinging may
occur: to rinse dropper with hot water to prevent contamination.","Oral: 5 mg 3-4 times a day; Child 1-6 years: 1-2 drops
0.01%, 6-12 years: 1-2 drops 0.25 %,> 12 years: 0.25 or 0.5%.","Increased heart rate, palpitation, tremors, ventricular
premature contractions and hypertension.",
PSEUDOEPHEDRINE,Syrup: 30 mg/5 ml; Tablets: 60 mg,"Nasal congestion associated with acute or chronic rhinitis,
common cold, sinusitis. In patients with otic inflammation or infection,
the drug may be useful in opening obstructed Eustachian tube. The drug
may be used as an adjunct to analgesics, antihistamines, antitussives when
indicated.","Use cautiously in patients with prostatic
hypertrophy, ischemic heart disease, glaucoma and diabetes mellitus.","60 mg 3-4 times daily; child 4 mg/kg/day per oral in 3-4
divided doses.","Nervousness, restlessness, dizziness, insomnia, headache
and drowsiness. Larger doses may cause lightheadedness, nausea and /or
vomiting.","Do not use with MAOIs or tricyclics;
hypertensive crisis may occur.
Patient information: Do not crush, divide, chew or dissolve, avoid taking drug
near bed time because stimulation can occur."
